

Annual Report

2021

Contents

Forewords	2
About Us	3
Mission and Vision	4
Our History	5
Executive Director Report.....	7
Our Strategy	8
Our Programs	9
Mother & Baby	9
Chronic & Integrated Care	11
Cancer.....	13
Neuroscience	15
Health Care Delivery & Innovation	17
Our Year At A Glance.....	19
Research Advisory Board	20
Students	21
Director Operations Report	22
Director Biomedical Research Report	23
Career Track Fellows	24
Equity, Diversity and Inclusion Committee	25
Mater Research Showcase & Future Leaders Symposium	26
Awards	27
2021 Grant Successes (Lead Investigators only).....	29
Publications	32

Forewords

Mater established its Research Advisory Board in March of 2021 and I am delighted to provide an introduction to this annual report on its behalf.

We would like to acknowledge the enormous contribution to medical science by so many Mater researchers ably led by Professors Maher Gandhi and Allison Pettit.



Mater Research has had a very productive and successful year, rising to the challenge of COVID-19 and again excelling in peer reviewed grant awards. 2021 was a stellar year for the Stillbirth team, led by Prof Vicki Flenady. Amongst notable achievements were a \$2M grant from the Department of Health to roll out the safer baby bundle and successful NHMRC Centres for Research and Investigator grant applications. In recognition of her contributions, Vicki was invited to represent Australia on the World Health Organisation forum on stillbirth.

The pandemic has demonstrated to the broader community and government the value of science and medical research and Mater's researchers have risen to the COVID challenge. Dr Mitchell Sullivan and A/Prof Katharina Ronacher are leading respective laboratory-based initiatives to target the SARS-CoV-2 virus and A/Prof Kym Rae is building a consortium to understand factors that will increase vaccine uptake in expectant mothers from the indigenous community. Yet, despite the pandemic, the devastating human impact of other diseases has not decreased and Mater Research has maintained its critical research programs in mother and baby research, chronic diseases, cancer, neuroscience and healthcare delivery and innovation. This would not have been possible without the continued strong support of the Mater Foundation and the donors who so generously support it.

Mater's research is maturing and a number of projects are being translated into clinical practice or commercial development, including a start-up company, based on A/Prof Sumaira Hasnain and her team's work to reverse liver damage, which attracted \$1.3M in seed funding; a new theranostic is moving into clinical trials in ovarian cancer patients; novel treatments for the life-threatening complications of diabetes and an early diagnostic for their detection; and combination therapy options to improve outcomes in melanoma and cervical cancer.

The Research Advisory Board congratulates the students who have achieved success in awards, attesting to their skills and dedication as well as the support of their supervisors and mentors. We look forward to continued success in 2022.

Dr Carrie Hillyard, Research Advisory Board Chair

Mater Foundation is delighted to play a role in connecting and enabling the community to directly support world-class medical research. The real beneficiaries of Mater Research's work are the community, who benefit through improved health.

Mater research delivers real benefits to patients. This is evidenced through many successes, and no more so than the 118 new research studies approved in 2021. Of those, three quarters were clinical studies aimed towards translation and implementation of research into better health outcomes with the remaining being discovery-based research using clinical samples or data.

The commitment and focus to improving the lives of others through discovery, refining, and translating medical research is evidenced by the 54 clinical trials testing an intervention like a new drug or treatment pathway and 34 cohort studies designed to observe predictive risk factors or health outcomes over time. Mater Research's work is truly bench to bedside, aligned to Mater's clinical specialists, and supported by Mater Education's focus on embedding improved clinical practice. This unique combination of researchers, clinicians, and educators ensure the generous support received from the community's generosity delivers tangible health benefits to patients.

This Annual Report demonstrates the exceptional researchers, facilities, collaborations, and research programs, however most of all it demonstrates Mater Research's focus on empowering people to live better lives through improved health and well-being.

Mr Andrew Thomas, Executive Director Mater Foundation




About Us

Mater Research is a recognised leader in medical research and the research arm of Mater. Our bench to bedside philosophy sees us working across Mater Health's hospitals and health services, and our partners The University of Queensland, the world-class [Translational Research Institute \(TRI\)](#) and [Health Translation Queensland](#). We are committed to working closely with [Mater Health](#), [Mater Education](#) and our growing network of partners and collaborators to turn scientific discovery into the best possible treatment, care, and outcomes for patients and our broader community.

Our strong track record of successful grant applications and fellowship recipients is underpinned by the significant financial support of [Mater Foundation](#). Millions of dollars are contributed each year funding pilot trials and projects, vital infrastructure and resources, student scholarships, backfilling clinical time to enable more clinician-led research, fellowships for our senior researchers and flexibility to sustain research beyond short-term grants.

With expertise across all facets of medical research—study design, ethics and governance, data collection, biobank management, analysis, and implementation science—we are responsible for robust management of all research and clinical trials at Mater. We also maintain a broad external focus, horizon scanning national and international high quality research to reduce duplication of effort and wasted resources, working alongside Mater Education and Mater Health to support prompt and efficient translation of research into clinical care.



Mission and Vision

Vision

To translate our research discoveries and integrate them into improved healthcare.

Mission

To **discover** new knowledge central to the Mater mission, **translate** this knowledge into practice and **integrate** these research outcomes into improved healthcare and educational practices across Mater.

Mercy Values


Mater Research wholeheartedly commits to the [Mater Values](#):

- We honour and promote the dignity of human life and of all creation
- We act with compassion and integrity
- We strive for excellence.

Mater Research

In addition to the Mercy Values, working across our five research programs Mater Research is committed to upholding the values relating to our scientific, medical and management mission:

- Integrity - we conduct ourselves and our work honestly and ethically to build a culture of excellence.
- Innovation - developing and extending knowledge to improve health.
- Inspiration - educating and imparting knowledge to inspire each other and future generations.
- Engagement - fostering and encouraging teamwork, collaboration and commitment to the community.



Our History

The establishment of a medical research institute at Mater Hill was a long-term goal of the Sisters of Mercy and the Mater Health Services Governing Board. This desire and commitment culminated in July 1998 with the formation of the Mater Medical Research Institute, a development funded by the Sisters of Mercy and their supporters. The Governor-General officially opened the institute in March 1999. In 2006, Mater Research incorporated and became a [National Health and Medical Research Council \(NHMRC\)](#) accredited independent medical research institute.

Mater Research commenced operation in 1998 with 10 staff. Since then, it has experienced significant growth, creating an internationally competitive institute with many original programs attracting top scientists from around the globe.

Mater Research has documented significant outputs in publications, patents, student achievements, collaborations, peer-reviewed funding and other significant funding.

The initial scientific focus for Mater Research was cancer immunology, however the research has grown to seed and attract other independent scientific teams. The institute now has five Research Programs, closely integrated with the clinical services at Mater Health.


The expansion of the research themes at Mater Research is in part a result of the close and effective working relationship established between Mater Research and Mater Health. Working together on significant joint ventures, confirms the link between medical research and its clinical application and this relationship continues to strengthen.

Mater Research has also proved its capacity to attract funding for ongoing developments and is a proud partner in the TRI, a \$354 million facility built on the Princess Alexandra Hospital site. With access to this infrastructure since January 2013, Mater Research has continued to grow rapidly both on the Mater campus and in the purpose-built TRI providing world class facilities for our biomedical research, including access to small-medium clinical grade manufacturing facilities.

The University of Queensland, a global top 50 university, has been an affiliate organisation from the institute's inception and is an increasingly important partner. In 2013, Mater Research and [The University of Queensland](#) formalised a long-standing relationship to form the Mater Research Institute – The University of Queensland (MRI-UQ). Merging the clinical expertise and high-quality health care of Mater with the research, education and training strengths of The University of Queensland provides strategic and operational benefits to both organisations to benefit healthcare. The collaborative alliance between Mater Research and The University of Queensland means that Mater Research is also a full institute within The University of Queensland Faculty of Medicine.

On 23 April 2013, canonical sponsorship for Mater was transferred to [Mercy Partners](#), which means Mater Research is now owned by Mercy Partners.

2016 saw Mater Research integrate further within Mater, the CEO joining the Mater Hospital Group Executive. In 2019 MMRI was rebranded as Mater Research Ltd and Professor Maher Gandhi was appointed as the Executive Director of Mater Research and MRI-UQ. In 2020 the research programs were enhanced with new leadership and alignment to reflect the changing needs of the community.



Executive Director Report


I hope you find this report as inspiring as I do. In these pages you will witness Mater Research's drive, passion and commitment to discovery, translation and integration. With this we serve the Mater community through cutting-edge health and medical research.

At Mater Research we know that our researchers are our core strength. Combined with our partnerships with The University of Queensland, the Translational Research Institute and Health Translation Queensland, we collectively leverage our networks to translate our findings to make a difference. In these pages, you will see numerous examples that illustrate this well.

Examples range across the health spectrum, including such diverse discoveries as the one by Freddy Beker's group that improved neurodevelopmental outcomes result by incorporating smell and taste into the feeding of preterm babies (*JAMA Pediatrics*); the characterization of new cancer cell enzymes that can be targeted by novel immunotherapies in malignancies of the breast and ovaries (published by John Hooper's team in *Nature Chemical Biology*); the ground-breaking discovery that we are NOT what we eat – (by Jake Grattan and colleagues in *Cell*), i.e. patients with Autism develop an altered gut microbiome and not the other way round; the continued success of JETRA including securement of substantial venture capital for Sumaira Hasnain's intellectual property to tackle obesity related liver disease; and the first psychosocial analysis of the burden of inflammatory bowel disease in young Australians by Simon Denny from the Mater Young Adult Health Centre.

The list goes on and on...


These and other successes have seen our institute grow and our reach expand. The breadth of these achievements is indeed a cause to celebrate. This has occurred despite the backdrop of considerable pressure on the sector due to limited research funding and philanthropy. Yet 2021 yielded our highest ever total for external international and national peer-reviewed grants – thereby bucking the national trend of diminishing funding returns and increasing competition for scarce research dollars.



Mater Research, like all around us, have had to struggle with the myriad of challenges that the pandemic has brought forth. Despite lockdowns, cessation in overseas higher degree student recruitment, supply chain issues and stop/start accrual to clinical trials, our overall productivity was largely maintained.

2021 could not have been navigated without the tenacity and leadership of my fellow executives Professor Allison Pettit and Emily Bailey, to the ongoing dedication of all of our research and professional staff, and the support of the Research Advisory Board and Mater Foundation. No one should take their commitment for granted, and I sincerely thank each and every single one of them.


As you can see, our research is having a global impact. I invite you to immerse yourself in our 2021 Mater Research Annual Report. I trust that you will be amazed and enlightened, and by the end feel as confident as I do, that 2022 will continue our upward trajectory.



Our Strategy

To achieve health impact through integrated research excellence:

- Develop the quality and output of researchers in Mater-relevant areas of focus.
- Enhance Mater's expertise in areas of excellence through high-quality research.
- Ensure the balance of research across discovery, translation and integration is aligned with Mater's strategy.
- Establish and maintain a strong culture of collaboration.
- Develop links with academic institutions and commercial agencies.
- Prioritise internal and external partnerships in areas of strategic focus.



In keeping with the values of Mater's founding Sisters of Mercy, Mater Research's five research priorities are borne of the most pressing health issues in the community. Each of our four health area/consumer targeted Programs (Mother & Baby, Chronic & Integrated, Cancer, Neuroscience) have activities across the spectrum of the discovery through translational research continuum with clear intent to solve significant health challenges. The enabling platform Program of *Health Care Delivery and Innovation* is well positioned to facilitate research integration within Mater's clinical services and lead innovation of healthcare delivery to set new standards of 'best practice'.

Our Programs

Mother & Baby

This program is focused on optimising the care of women and their babies during pregnancy and following delivery. Ongoing research activity is directed toward improving the clinical management of complications before, during and after pregnancy, optimising the care for premature and unwell neonates, and examining the relationship between fetal development, early life experience and life-long health. This program is home to the prestigious NHMRC funded Stillbirth Centre of Research Excellence. It also supports the Queensland Family Cohort Study, a landmark research project to track health across Queensland families.

Group Name	Group Leader
Centre of Research Excellence in Stillbirth	Professor Vicki Flenady
Critical Care of At Risk Newborns Research	Professor Helen Liley
Developmental Molecular Genetics Group	Dr Sandy Richardson
Genesis Maternal Fetal Medicine Research	Professor Sailesh Kumar
Indigenous Health Research	Associate Professor Kym Rae
Neurodevelopmental Follow-up and Outcomes Research	Associate Professor Samudragupta Bora
Pregnancy and Development Research	Professor Vicki Clifton

Program Leaders: Professor Vicki Flenady (Health Services) and Professor Helen Liley (Clinical)



Prof Vicki Flenady



Dr Sandy Richardson



Prof Helen Liley



Prof Vicki Clifton



Prof Sailesh Kumar



A/Prof Kym Rae



A/Prof Samudragupta Bora

Research Highlight: Mother & Baby Program

Dr Friederike Beker

Dr Friederike Beker is a Senior Staff Specialist in Neonatology at Brisbane's Mater Mothers' Hospital and a Mater Researcher in the Neonatal Critical Care Unit group. Enabled through a 2016 Betty McGrath Fellowship that allowed clinical back-fill and pursuing PhD studies, Dr Beker is exploring the role of taste and smell in premature baby development. Seven years ago, her partner, Chef Jan Gundlach suggested that even preterm infants could taste and would probably appreciate food. Hence, Dr Beker conducted a clinical trial with the question: For preterm infants, do regular smell and taste of milk with tube feeding, compared with routine care, improve nutrition and other clinical outcomes?



"We found very premature babies who were allowed to smell and taste milk at the same time as they were being tube fed, recorded slightly larger head circumference measurements and body length at 36 weeks compared to babies that didn't get the sensory stimulation."

Knowledge impact: In this randomized clinical trial of 396 preterm infants, regular exposure to the smell and taste of milk with tube feeding compared with routine care did not increase weight at discharge. This contrasts with a similar study also recently published (PMID: 31062377), identifying that site-specific factors may affect the outcome of this intervention. However, smell and taste of milk did improve head circumference and length at 36 weeks' postmenstrual age which has been previously associated with better long-term neurodevelopmental outcomes in pre-term infants. Consequently a 2-year neurodevelopmental follow-up of trial participants is underway to investigate this possible benefit. This Mater led and financed clinical trial has been published in the highly respected Journal of the American Medical Association (JAMA) Pediatrics. The publication of trial results received attention from media, social media and the neonatal community around Australia and beyond. Dr Beker was invited speaker to Cool Topics Neonatology in 2021 to present the study results to an international audience.

Community impact: This research is actively informing whether the simple intervention of introducing smell and taste of food should be incorporated into the regular care of very preterm babies. Effective interventions at this early stage in this vulnerable patient group have potential to have life-long implications for the health and wellbeing of the impacted families.

Chronic & Integrated Care

This program is focused on studying the pathophysiology and management of chronic diseases and using this information to direct discovery of new therapies and preventative strategies to address unmet needs. Research is currently being conducted into Type 1 and Type 2 diabetes and associated complications, inflammatory bowel diseases, chronic respiratory and infectious diseases, chronic liver disease and cardiovascular and renal disease.

Group Name	Group Leader
Genetics, Genomics and Transcriptomics Research	Professor Kim Summers
Glycation and Diabetes Complications Research	Professor Josephine Forbes
Hormones and Metabolism Research	Dr Helen Barrett
Immunopathology Research	Associate Professor Sumaira Hasnain
Infection, Immunity and Metabolism Research	Associate Professor Katharina Ronacher
Inflammatory Bowel Diseases Research	Associate Professor Jake Begun
Macrophage Biology Research	Professor David Hume
Stem Cell Biology Research	Professor Jean-Pierre Levesque

Program Leaders: Professor Josephine Forbes (Biomedical) and Dr Helen Barrett (Clinical)



Prof Josephine Forbes



Prof Jean-Pierre Levesque



Dr Helen Barrett



Prof Kim Summers



A/Prof Jake Begun



Prof David Hume



A/Prof Katharina Ronacher



A/Prof Sumaira Hasnain

Research Highlight: Chronic & Integrated Care Program

Professor David Hume & Dr Katherine Irvine

Professor David Hume and Dr Katharine Irvine co-lead the Macrophage Biology group. Their program of research is focussed on the biology of cells of the innate immune system called macrophages and their functions in development and disease.

Much of their research deals with the role of the macrophage growth factor colony stimulating factor 1 and its receptor in controlling normal physiology and disease. The team is working with sophisticated experimental tools to elucidate the biological impact of this signalling axis in macrophages including:

i) preclinical animal models with mutations in the colony stimulating factor 1 receptor gene that inhibit macrophage development, and ii) a novel stable form of colony stimulating factor 1 that stimulates macrophage development.



"This is basic science research, but it has clear implications for understanding the lifelong health impacts of low birth weight and prematurity in human infants"

Knowledge impact: Different kinds of mutations in the colony stimulating factor 1 receptor gene in humans cause a spectrum of diseases ranging from a severe postnatal developmental defect and infant mortality to an adult-onset neurodegenerative disease. Prof Hume and Dr Irvine's research showed that the loss of colony stimulating factor 1 receptor function severely compromises postnatal growth and development of the skeleton and multiple organ systems including the liver, leading to early mortality. In a separate study they have provided new insights into the mechanisms underlying neurodegeneration in adult-onset human disease. Very surprisingly, all of the detrimental impacts of genetic mutation in colony stimulating factor 1 receptor could be reversed by transfer of normal bone marrow cells in the early postnatal period. Unexpectedly this cell therapy even restored fertility in these animals. Some of these exiting findings have recently been published and have been used toward gaining grant funding from the Australian Research Council (ARC). Complementing these studies that highlight the fundamental role of macrophages in growth and development, the team is investigating whether colony stimulating factor 1 could be used to promote tissue regeneration. They have demonstrated striking impacts of treatment on liver fibrosis and regeneration, and gained project funding from the NHMRC and Metro South Hospital and Health Service to pursue this translational research.

Community Impact: Building on many years of discovery research of the Hume & Irvine team, these novel results provide evidence that the postnatal expansion of the innate immune system is a key event in normal development; and could provide opportunities for correcting chronic disease tissue damage and neurodegenerative disease. Translating these preclinical animal data into human health, this suggests a new avenue for using cell-based therapy to correct deficiencies in postnatal growth and development (low birth weight, failure to thrive) and immune cell function.

Cancer

Researchers within this program study the biological basis of solid and blood borne malignancies, and approaches to improving diagnostics. The continuing outcomes of this research are discovery, development and trialling of new therapies and diagnostics, as well as improving all aspects of the management of cancer for all patients, including palliative care.

Group Name	Group Leader
Blood Cancer Research	Professor Maher Gandhi
Bones and Immunology Research	Professor Allison Pettit
Cancer Biology Research	Professor John Hooper
Cancer Immunotherapies Research	Professor Kristen Radford
Palliative Care Research	Professor Janet Hardy
Smiling for Smiddy Cell Cycle Melanoma Research	Professor Brian Gabrielli
Stem Cells and Cancer Research	Associate Professor Ingrid Winkler
Translational Bioinformatics Research	Dr Adam Ewing

Program Leaders: Professor Kristen Radford (Biomedical) and Professor Janet Hardy (Clinical)



Prof Kristen Radford



Prof John Hooper



Prof Janet Hardy



Prof Allison Pettit



Prof Maher Gandhi



Prof Brian Gabrielli



Dr Adam Ewing



A/Prof Ingrid Winkler

Research Highlight: Cancer Program

Dr Thomas Kryza

Dr Thomas Kryza is a Research Officer in the Cancer Biology Research Group led by Prof John Hooper.

Enabled through recent prestigious funding from the National Breast Cancer Foundation's "Love Your Sister" initiative, Dr Kryza's goal is to discover new methods for earlier diagnosis of breast cancer and better treatments for women who have this disease.

His research is focused on understanding the causes of breast and other cancers and the development of innovative molecules that can be used to deliver radioactive particles and drug payloads specifically to cancer cells so that they can be more easily and accurately be detected for diagnosis and so that patients have more effective treatments. Dr Kryza collaborates closely with breast cancer clinician researchers from Mater's Pathology Department, in particular Dr Cameron Snell.

Knowledge impact: In a key breakthrough for the field, in an article published in the prestigious journal *Nature Chemical Biology*, Dr Kryza and Prof Hooper reported the development of novel tools to revolutionise how cell enzyme networks are studied in cancer and other debilitating diseases. The work will allow the identification of cancer-enriched molecules that promote the most aggressive forms of cancer that spread (metastasize) to other organs in the patient's body. Importantly, these molecules have the potential to be used positively for both earlier diagnosis and more effective treatment of cancer.

Community impact: From their research discoveries over the last 20 years, the team led by Prof Hooper is currently conducting a clinical trial testing one of their new biological agents for the ability to act as a 'Trojan Horse' to specifically deliver radioactive payloads to ovarian cancer cells. This kind of "precision medicine" is expected to lead to better patient survival rates with patients experiencing fewer toxic side effects.



"Our project has the potential to revolutionise the clinical management of breast cancer by improving both detection and treatment to significantly improve the quality of life and survival of breast cancer patients."

"Because this agent is already in clinical testing for ovarian cancer, if the research team can demonstrate it is also applicable to breast cancer, it will hopefully be available to patients faster."

Neuroscience

This program focuses on the genetics and pathophysiology of diseases of the brain and nervous system and seeks to improve the life-long management across the spectrum of neurological disease, intellectual disability and mental health conditions. A strategic partnership with UQ's Queensland Brain Institute provides a nexus to world-class research calibre (people, technology, infrastructure).

Group Name	Group Leader / Clinical Lead
Cognitive Health Genomics	A/Prof Jake Gratten
Cognitive Neurology	Professor Peter Nestor
Neurodevelopmental Research	Associate Professor Paul Dawson
Epilepsy Research	Dr Lisa Gillinder
Genome Plasticity and Disease Research	Professor Geoffrey Faulkner
Neuroimmunology Research	Dr Andrew Swayne
Neural Stem Cell Biology Research	Dr Dhanisha Jhaveri

Program Leaders: *Dr Dhanisha Jhaveri (Biomedical) and Dr Lisa Gillinder (Clinical)*



Dr Dhanisha Jhaveri



A/Prof Paul Dawson



Prof Geoffrey Faulkner



Dr Lisa Gillinder



Prof Peter Nestor



A/Prof Jake Gratten




Dr Andrew Swayne

Research Highlight: Neuroscience Program

A/Prof Jake Gratten

A/Prof Jake Gratten is the leader of the Cognitive Health Genomics group at Mater Research. A/Prof Gratten has authored more than 50 publications, including many in high-ranking journals such as *Nature Genetics*, *Nature Neuroscience* and *Cell*. As lead investigator, he has received competitive funding from NHMRC, including a recent Ideas grant, and Autism CRC Limited, the world's first national cooperative research centre effort focused on autism.

A/Prof Gratten and his team perform research on the genomics of neurodevelopment and neurodegeneration with the aim to improve understanding of the causes of psychiatric and neurological disorders such as autism, schizophrenia, Parkinson's disease (PD) and multiple sclerosis (MS). The ultimate purpose is to advance the diagnosis, treatment, and prevention of neurological illnesses, improve the quality of life for affected individuals and reduce associated health care costs. Using his recent NHMRC Ideas funding, Jake wants to understand the genetic basis of PD and identify new drug targets to treat this devastating neurodegenerative condition affecting 1% of Australians aged 60-years and over.



"I made the decision to focus my research career on the genomics of mental health because I am driven to make discoveries that translate into improved quality of life and treatment options for the many people living with psychiatric and neurological disorders."

Knowledge impact: In a large Australia wide study A/Prof Gratten's team, in particular PhD student Chloe Yap, examined genetic material from stool samples of 247 children, including 99 children diagnosed with autism. The researchers found changes in the gut microbiome of people on the autism spectrum appear to be due to restricted eating behaviour which is more common among autistic children due to sensory sensitivities or restricted and repetitive interests. Published in prestigious journal *Cell*, the data suggested that behaviour and dietary preferences affect the microbiome, not the other way around.

In another study, published in the prestigious journal *Nature Communications*, A/Prof Gratten and national collaborators used genomic analyses to assess a potential link between MS and inflammatory bowel disease (IBD), as these diseases frequently co-occur but the underlying biological mechanisms remain unclear. This study sheds light on the biological basis of MS-IBD comorbidity and addresses one of the major challenges for doctors in immunology and gastroenterology clinics, i.e. how to treat patients with both MS and IBD, because commonly prescribed medications for MS can exacerbate IBD symptoms and vice versa.

Community impact: The autism study's findings (*Cell* paper) have challenged the growing popular belief that the gut microbiome drives autism. Given it is the most comprehensive study of its kind, it provides compelling evidence that experimental use of microbiome-based interventions such as faecal microbiota transplants and probiotics, that had growing interest for treating autistic behaviours, are unlikely to be effective. The research by A/Prof Gratten's team has attracted broad community interest as evidenced by a recent article in *The Economist*

<https://www.economist.com/science-and-technology/can-an-upset-gut-microbiome-cause-autism/21806337>

Health Care Delivery & Innovation

This program focuses on facilitating research that improves the care and wellbeing of people accessing health services at Mater Health and across the nation, through the development and design of robust, effective, multidisciplinary clinical questions that translate into effective practice and policy. This activity has impact across all the Mater Research Programs and Mater Health disciplines. This program brings together education, health economics and implementation science, with active consumer input to address research topics of relevance to the community. Many Mater Clinicians and educational specialists also actively undertake health services research across Mater campuses.

Group Name	Group Leader
Allied Health Research	Dr Liisa Laakso
Living Well with Cancer Research	Professor Sandie McCarthy
Mater Young Adult Research	Associate Professor Simon Denny
Queensland Centre for Intellectual and Developmental Disability	Dr Cathy Franklin

Program Leaders: Professor Sandie McCarthy and Associate Professor Simon Denny



Prof Sandie McCarthy



A/Prof Simon Denny



A/Prof Liisa Laakso



Dr Cathy Franklin

Research Highlight: Health Care Delivery & Innovation Program

Associate Professor Simon Denny

Associate Professor Simon Denny is the Director of the Mater Young Adult Health Centre (MYAHC) and is a Program Co-Leader of the Health Care Delivery & Innovation research program at Mater Research. Associate Professor Denny's research is currently focused on understanding how health services can help young people struggling with complex health issues that are impacting on their wellbeing. Associate Professor Denny has authored over 80 publications and has received more than \$10m in competitive funding from the national and international institutions. Associate Professor Denny and his team integrate with many other research programs of Mater and work collaboratively across Australia and New Zealand. His research contributions have been recognized with international awards, editorials and invitations to present at international conferences. He is currently Chair of the Adolescent and Young Adult Medicine Committee for the Royal Australasian College of Physicians.




"I believe that by helping young people during their critical adolescent years we can ensure that they lead healthier and happier lives as adults"

Knowledge impact: In a published study (Intern Med J 2021) Associate Professor Denny's team examined the psychosocial burden of inflammatory bowel disease (IBD) in young people aged 15-25 years attending MYAHC, a tertiary specialist health centre for adolescents and young adults in Brisbane. The aim was to describe the impact of IBD on psychosocial well-being in young people and to compare well-being in the IBD cohort to well-being among young people with other chronic conditions, with a view to identifying characteristics and challenges unique to those with IBD. When comparing surveys from 51 young people with IBD with 210 young people with other chronic diseases, young people with IBD reported higher depressive symptoms, worse illness perceptions and lower internal locus of control.

Community impact: The results indicated that early recognition and treatment of depression and other psychosocial comorbidities within integrated pathways of care is crucial in improving the standard of care in adolescents and young adults with IBD. These interventions are likely to improve the course of IBD and their overall health and well-being.

Our Year At A Glance



Research Advisory Board

The Research Advisory Board is established to provide independent strategic advice on clinical research or scientific related matters to the Mater Research Executive Leadership and Mater Chief Executive Officer.



Advisory Board Chair

Dr Carrie Hillyard is Chairman of Fitgenes Limited and a director of the Academy of Technology and Engineering (ATSE). Previously, she was a co-founder of venture fund, CM Capital Investments, a director of several of its investee companies and led its Life Sciences group for 14 years. Dr Hillyard served as Deputy Chair of the Mater Research Board from 2007 – 2020.



Advisory Board Member

Professor Denise Doolan is Deputy Director of the Australian Institute of Tropical Health and Medicine at James Cook University, and Director of the James Cook University Centre of Molecular Therapeutics. She is a member of the national expert advisory panel The Australian Medical Research Advisory Board.



Advisory Board Member

Professor Frank Gannon was the Director and CEO of QIMR Berghofer Medical Research Institute from 2011 to 2020 and has been the Director General and board member of Science Foundation Ireland (The Irish Research Funding Agency) since 2007.



Advisory Board Member

Professor John Savill has been Executive Director of the Melbourne Academic Centre for Health (MACH) since July 2019, having served in the United Kingdom as an honorary consultant in renal and acute medicine from 1990 to 2018.



Advisory Board Member

Professor Karen Moritz was appointed the Director of the Child Health Research Centre in 2016 and in 2021 became the Associate Dean of Research at the UQ Faculty of Medicine.

Students

Record numbers of HDR students and student accolades have substantially contributed to Mater Research's success in 2021. Many of the HDR students hosted at Mater Research are enrolled through The University of Queensland representing a significant mutual benefit of our partnership. A summary of those achievements and activities over the past year are listed below.

Student metrics

- HDR students: Total 107 (52 clinical and 55 biomedical)
Conferrals: 10 PhD (5 clinical and 5 biomedical)
- Honours students: Total 17 (includes 2 current students mid-21 to mid-22)
Degrees awarded: 13 First Class and 2 Second Class

PhD Student accolades

- Rosie Stoke, Winner 2021 Faculty of Medicine and 2021 University of Queensland 3MT & 2021 Asia Pacific 3MT semi-finalist. First Prize Oral Presentation 2021 University of Queensland Medical Student Research Conference and Showcase
- Lena Batoon, The inaugural "PhD Graduate of the Year" University of Queensland Faculty of Medicine.
- Jennifer Stables, Winner – 2021 PA Hospital Symposium Researcher of the Year
- Chloe Yap, 2021 Queensland Women in STEM Prize
- Andrew Swayne, Winner 2021 Dr Laurence Catley Research Student Prize
- Tom Mullins, Winner 2021 Dr David Serisier Student Training Award
- Liam O'Brien, Winner 2021 Mater Research HDR Biomedical Prize
- Aleysha Martin, Recipient of a NHMRC PhD scholarship 2021-2023
- Cheng Xiang Foo, Queensland Finalist for the 10xGenomics Illumina Awards

Activities of the Mater Student Research Committee: meeting monthly - Prof Brian Gabrielli (Chair), Dr Kylie Alexander (Dep. Chair), Ms Sarah Doyle (student recruitment and administration officer), A/Prof Paul Dawson (Head of Education), Dr Norbert Kienzle, Prof Liisa Laakso, Dr Christine Andrews, Dr Thomas Kryza, Dr Camille Guillerey, and student reps Jennifer Stables, Thomas Mullins, Madeline Gough, Hareshh Sajjir.

- Reviewed 38 new student applications (18 PhD and 20 Honours)
- Future Leaders Symposium at TRI
- Student Information Event at TRI and virtual, to attract new students in 2022
- Mater Research 3MT
- Social events, including Monthly Mater Research Mixer at Brewhouse, and 3-monthly morning teas
- Mater Research Honours student presentation events mid- and end-of-year

New initiatives and recognition

- Developed/implemented an effective process to capture and share student information with the University of Queensland Research Partner Managers to expedite the University of Queensland Mater student research agreements process.
- Weekly 'Happy Wednesday' email to all Mater Research students and supervisors to communicate important Mater, The University of Queensland and TRI student-specific updates, as well as maintain morale during the covid pandemic.
- As a result of the year-on-year growth of the Mater HDR student cohort (reaching 100+ in 2021), The University of Queensland Faculty of Medicine appointed A/Prof Paul Dawson as the Director of HDR to review and approve MRI-UQ HDR student online submissions/requests to The University of Queensland Graduate School.
- For contributions to the success of the Mater Research student cohort activities and outcomes in recent years, Prof Brian Gabrielli, Ms Sarah Doyle and A/Prof Paul Dawson were nominated by Mater Research for the 2021 The University of Queensland Faculty of Medicine Service Excellence Award.

Director Operations Report

Emily Bailey

Collaboration is central to success in research, and our Operations team at Mater Research aim to bring that same collaborative focus to our support for the back-of-house functions of the Institute. Throughout 2021, we have endeavoured to stop and think about the way we support research and researchers and ensure we're continuing to provide this support efficiently and effectively. In some instances, change will come through Mater-wide systems upgrades such as the new Dynamics 365 Finance system which will roll-out in 2022. In other areas our teams are working to develop different ways of conducting our business, such as extensive work undertaken by our Compliance team to develop a more streamlined approach to entering into agreements with our local University partners, and our Grants team continuing to improve our capture of research grant data and support more efficient post-award establishment. Since January 2021, the median time from grant announcement to establishment (issue of Grant Record Letter) has reduced significantly. There is more work to be done, but we're heading in the right direction. Alongside our focus on continuous improvement, our support teams have also had to adapt to the constantly changing research environment that the COVID-19 pandemic has created.



The past twelve months has also seen considerable change amongst the staff of Mater Research's Operations team. In February, Dr Maree Knight stepped down as Director of Operations after 12 years with Mater Research, to take on a new role as Director of Innovation across the Mater group of companies. This change has afforded me the privilege, and challenge, of joining Mater Research to lead the Operations portfolio.

In March, our Clinical Trials Unit (CTU) Manager, Anne Tremellen, moved to a new organisation after 37 years' service to Mater first as a midwife and later as a midwifery researcher, and then supporting the development of the CTU for Mater Research from 2017. This change saw us welcoming Amrit Hayer to the CTU Manager role from May 2021.

In December 2021 we also farewelled Norbert Konecki, Manager of our IT team, after 23 years of dedicated service to Mater Research. Throughout 2021, Norbert was instrumental in helping me to understand the complexities of the Mater Research IT network, and in developing a new Data Storage infrastructure solution for Mater Research which will be rolled out in mid-2022.

After almost a year working with the teams in the Operations portfolio, I am excited to welcome 2022 and continue to improve the way we support research and researchers at Mater Research.

Director Biomedical Research Report

Professor Allison Pettit

As per Mater Research's strategy, our biomedical discovery research activity has established intent to address significant health challenges and continue to deliver on this in 2021. Many of these research projects are enhanced through clinical collaborations within Mater Health and beyond and utilise clinical samples, large clinical/population datasets, or preclinical models of disease. Significant progress has been made by many teams toward discovery of novel pathogenic mechanisms, identification of new therapeutic targets and development of new treatments/diagnostic. This has all be aided by the state-of-the-art facilities at TRI giving Mater researchers streamlined access to enabling core facility platforms and infrastructure that underpin innovative biomedical research approaches.



Progress has been made toward translation of biomedical discoveries made at Mater Research including:

- Prof Kristen Radford and her team's ongoing development of a targeted cancer vaccine.
- A/Prof Sumaira Hasnain's team continuation of vital pre-clinical research for biotech company Jetra Therapeutics, to support the development of a potential new treatment to reverse obesity-related liver disease. Jetra Therapeutics is a spin-off company from The University of Queensland which holds the license for a patent protected discovery on which this new treatment is based and was made by A/Prof Hasnain and several other Mater Researchers.
- Facilitated through MRFF success, Prof John Hooper's team is developing a new theranostic with plans for this to be trialled in ovarian cancer patients in 2023.
- A new Australian collaborative Autism CRC study, led by Mater Research's A/Prof Gratten challenged the growing popular belief that the gut microbiome drives autism, providing compelling evidence that experimental use of microbiome-based interventions that had growing interest for treating autistic behaviours, are unlikely to be effective.
- Prof Forbes' team continue to work with biotech industry partners to develop innovative treatments for complications of diabetes. They also ruled out a non-invasive approach as an early diagnostic for early detection of people with diabetes who are at risk of developing life-threatening complications but continue to search for improved early predictors of complications.
- Prof Gabrielli is working closely with biopharmaceutical companies to explore combination therapy options to improve outcomes in melanoma and cervical cancer.

I've been privileged to lead Mater Research's internationally competitive biomedical research workforce in 2021 and through providing an enabling environment, have endeavoured to support them in their continuing success of delivering knowledge and health impacts.

Career Track Fellows

Mater Research recognises that for full-time health researchers the period between postdoctoral research and establishment of research independence is often challenging. Premature transition to independence can lead to problems associated with inadequate resources and investigators can struggle with the challenges of recruiting and managing a research team. Newly formed smaller teams are vulnerable to the vagaries of grant funding, with this economic instability impacting productivity. Consequently, it is important to provide high potential emerging investigators with a pathway to progressively build stepwise independence in a supportive environment that provides a high level of mentoring and exposure to research leadership mechanisms and research group management responsibilities. This is the purpose of Mater Research's Career Track Fellow (CTF) program. Previous CTFs who have transitioned to independence include A/Prof Sumaira Hasnain, Dr Adam Ewing and Dr Sandy Richardson. Mater Research is current mentoring five CTFs:

Dr Ran Wang (Stem Cells and Cancer Research Program) focuses her research on diseases that arise as a result of inflammation or infection in the gut and lungs, such as ulcerative colitis and lung fibrosis. She has particular interest in understanding why inflammation happens, and the associated consequences to the surrounding tissue (e.g. tissue damage) and other organs (e.g. osteoporosis, muscle wasting). Her longer-term goal is to exploit this knowledge to devise novel therapeutic strategies for treat gut inflammation as well as complications induced by the inflammation.

Dr Camille Guillerey (Cancer Immunotherapies Research Group) is currently focused on Natural Killer cells, a population of immune cells that recognise and kill cancer cells. She is interested in understanding how Natural Killer cells interact with other immune cells to develop protective immune responses since improved basic knowledge of immunological processes will help design new therapies for various human pathologies such as cancer, infectious disease or autoimmune disorders. In addition, Camille aims to identify mechanisms that may prevent Natural Killer cells from eliminating cancer cells and apply these findings to develop new treatments for childhood leukemia.

Dr Seth Cheetham (Genome Plasticity and Disease Research Group) is a molecular biologist and biochemist with a focus on molecular mechanisms of gene regulation. He has a long-term interest in the functions of the so-called 'junk' DNA—noncoding DNA regions scattered randomly throughout the genome with no obvious function—and its role in human biology. He is investigating whether pseudogenes contribute to cancer development and progression.

Dr Mitchell Sullivan (Glycation and Diabetes Complications Research Group) believes that by investigating the processes involved in how our bodies store the sugar in our tissues, it will be possible to unravel the origin and potential treatments of metabolic diseases such as diabetes. He has a keen interest in the role of a molecule named glycogen, which is a readily mobilized storage form of blood-sugar present in tissues like the liver and kidneys.

Dr Katharine Irvine (Macrophage Biology Research Group) is developing research projects investigating the role of macrophages in the progression and complications of chronic liver disease, as well working on new collaborations in area of Chronic Diseases with Mater's clinical team. She has a strong focus on clinical and translational research and hopes to deliver research outcomes that will benefit patients and change healthcare practice.

Equity, Diversity and Inclusion Committee

The gender equity initiative was formalised at Mater Research in 2016 and has evolved to encompass diversity and inclusion more broadly. The aim of our Committee is to promote the embracement of diverse backgrounds, experiences, and identities across Mater Research. The past year has been a challenging one, as we navigated a global pandemic. Our priority in the past 18 months has been to embed the equity, diversity and inclusion Committees' presence and increase our commitments and accountability at Mater Research.



In the past year we have:

Continued efforts to promote diversity

- Reached gender/career stage balance on the EDI committee
- Auditing and reporting on diversity considerations for Mater Research led symposia
- Improve capacity in cultural training by sponsoring attendance to BlackCard Program

Increased awareness and brought initiatives to bolster equity

- Helped bring the vacation care program to TRI for parents
- Led the assessment of Strategic grant for Outstanding Women
- Led the first in Australia screening of 'Picture a Scientist'
- Organised the International Women's Day Function
- Five EDI committee members committed to join the first responder network which provides a safe and supportive environment for survivors of sexual assault and/or harassment

What we would like to do next:

This year our aim to provide workshops to help researchers recognise and mitigate bias, practice self-care, explore their diverse identities, engage in allyship and to encourage senior researchers to leverage their influence to mentor and sponsor Early/Mid-career researchers.

Each one of us has a role to play in building a more equitable, inclusive, and diverse work environment, and we are committed to promoting this at Mater Research. To ensure we are as impactful in these efforts as possible, we welcome any feedback you may have. You can reach us at any time on ediresearch@mater.uq.edu.au or come see us in person.



Mater Research Showcase & Future Leaders Symposium

The Showcase and the Future Leaders Symposium are the highlights in the Mater Research events calendar. They provide Mater Research's best biomedical, clinical and health care researchers an opportunity to share their research outcomes using a broadly accessible communication approach. It is also an opportunity to thank key Mater Research staff for their passionate dedication throughout the year via the Mater Sisters of Mercy Medals and other prizes. The Research Engagement Team successfully navigated the ever-changing COVID-19 safe plan requirements with the events proceeding as planned via a mix of in person and video presentations and communal networking sessions.

The events are important platforms for early career researchers (ECR) and students to hone their presentation skills so their research advancements and impacts can resonate with the community. To assist with this, Mater Research, together with Mater Foundation, invest in the BRIDGE program, which is designed to train researchers in communicating their discoveries to a lay audience.

The Mater Research Future Leaders Symposium was held at the Translational Research Institute on 25 Oct 2021. This event celebrated the work of the up-and-coming leaders of Mater's biomedical and clinical research fields. A highlight of this event was the selection of Mater Research Early Career Researcher Seeding Grants, that were judged via a competitive process of a written project proposal and a persuasive presentation to an audience of dignitaries and donors; the two successful grants were subsequently presented at the Mater Research Showcase. Likewise, higher degree research students and Early Career Researchers competed for a number of awards and prizes based on their effective presentation skills and/or career track records. A full list of winners can be found in the Awards sections of this report.

The annual Mater Research Showcase, held at TRI in Brisbane on 10 Nov 2021, was a wonderful opportunity to celebrate the outstanding, world-class research contributions and achievements of our emerging and established biomedical and clinical researchers. More than 120 people attended the Showcase in person, including the State Assistant Minister for Health and Regional Infrastructure, Julieanne Gilbert MP, Mater Group, Foundation, Education, Health, and Research Executives, Mater Board and Mater Research Advisory Board members, TRI and University of Queensland Executives, Mater Research Program and Group Leaders, and researchers and staff. Numerous people also attended online.



Indigenous Songwoman Maroochy performed the Welcome to Country ceremony, after which senior research presentations were delivered by A/Prof Paul Griffin and Professors Vicki Flenady, Sandie McCarthy and Geoff Faulkner. Brisbane Sister of Mercy and member of the Mater Misericordiae Limited Board, Sr Sandra Lupi RSM, delivered a special reminder of the First Nations people who were the first scientists in Australia, and then spoke about the Sisters of Mercy who pioneered research at Mater from the early 1900's onwards. Sr Sandra also presented one of the highlights of the Showcase - the Mater Sisters of Mercy Medals.

Awards

Internal Awards

Betty McGrath Seeding Grants – Health Care Delivery & Innovation

Dr Grace Branjerdporn, 'Effectiveness and cost-effectiveness of an electronic mindfulness-based intervention to improve maternal mental health in the peripartum: A randomised controlled trial'.

Dr Peter Collins, 'Digital-health enhanced Mater Malnutrition Model of Care in supporting patients with chronic obstructive pulmonary disease (COPD): from hospital-to-community transition'.

Dr Lisa Gillinder, 'Language in Epilepsy Assessment Program – LEAP Project'.

Ms Bronagh McAlinden, 'Investigating inter-rater reliability for the use of lung ultrasound by physiotherapists in premature infants with Respiratory Distress Syndrome'.

Dr Kym Warhurst, 'Engaging with clinicians to identify and reduce unwarranted clinical variation in maternity care'.

Betty McGrath Seeding Grants – Education

Ms Sharon Clipperton, 'Development and evaluation of a faculty development program for Translational Simulation'.

Dr Erich Schulz, 'Teaching tip lifting to medical students — An adaptive three arm effectiveness RCT to improve intravenous cannulation first time success: Flatten and Advance while Lifting the Tip (FALT) Trial'.

Dr Laurence Catley Clinical Student Prize – Dr Andrew Swayne

Early Career Researcher Prize – Dr Katie Brooker

Early Career Researcher Seeding Grants

Dr Kavita Bisht, 'Delineating the role of oncostatin M on pathobiology of myeloproliferative neoplasms and aging'. (Biomedical)

Dr Katie Brooker, 'Evaluation of an online module to improve medical student knowledge and self-efficacy to support Autistic patients'. (Clinical)

Higher Degree Research Biomedical Prize – Mr Liam O'Brien

Dr David Serisier Student Training Award – Mr Thomas Mullins

Mater Family Wellbeing Service Best Start Grant

Ms Angela Lane, 'Application for funding for completion of Graduate Certificate in Perinatal Infant Mental Health'.

Dr Constanze Schulz, 'Developing a new perinatal mental health service'.

Dr Julanne Frater, '"The Other Half" – Perinatal Mental Health Services for Fathers and Partners – Keeping the family in mind as a matter of routine care in the perinatal period'.

Ms Sheridan Guyatt, 'Supporting mothers to develop skills in mindfulness, relaxation, breathing, movement, exercise and infant play through a group intervention: A Physiotherapy approach to improving the mental health of postnatal women'.

Publication Recognition Scheme

Prof Josephine Forbes – Clinical Award (Round 1)

Dr Danielle Borg – Clinical Award (Round 1)

Dr Seth Cheetham – Biomedical Award (Round 1)

Thomas Kryza – Biomedical Award (Round 1)

Prof Vicki Flenady – Clinical Award (Round 2)

Dr Friederike Beker – Clinical Award (Round 2)

Dr Yuanhao Yang – Biomedical Award (Round 2)

Ms Chloe Yap – Biomedical Award (Round 2)

Sisters of Mercy Medals

Ms Amanda Sands – The Sister Madonna Josey Medal
Dr Sandy Richardson – The Sister Michaelaheen Ahern Medal
Dr Adam Ewing – The Sister Regis Mary Dunne Medal
Dr Lucy Burr – The Sister Eileen Pollard Medal

Special Award – Dr Maree Knight

Strategic Grant for Outstanding Women – A/Prof Kym Rae

External Awards

Australian Health Research Alliance (AHRA) Women's Health Research, Translation and Impact Network (WHRIN) EMCR Award – Dr Danielle Borg

Flying Scientist – Dr Lena Batoon

Franklin Women Teresa Anderson Award – Dr Kavita Bisht

Fresh Scientists - Mr Liam O'Brien; Dr Andrew Swayne

Mater People Awards

A/Prof Sumaira Hasnain – Mater Research Excellence
Dr Julie Cichero – Mater Leadership (Emerging Leader)

Member of the Order of Australia – Prof Claire Jackson (AM)

Women in Technology

Professor Josephine Forbes – Outstanding Achiever Science Award (winner)
Ms Chloe Yap – Emerging Achiever Award (highly commended)

Queensland Women in STEM – Ms Chloe Yap (judges award)

The University of Queensland Faculty of Medicine PhD Student of the Year Award

Dr Lena Batoon (winner)
Dr Josh Tobin (runner-up)

2021 Grant Successes (Lead Investigators only)

National Health Medical Research Council

Prof David Hume, Investigator grant, 'Regulation and function of the macrophage colony-stimulating factor receptor (CSF1R)', \$3,427,015.

Prof Vicki Flenady, Investigator grant, 'Preventing stillbirth and neonatal death and improving care after loss', \$3,372,570.

Prof Josephine Forbes, Investigator grant, 'Designing and translating novel therapies for diabetes and kidney disease', \$2,372,570.

Prof Sailesh Kumar, Investigator grant, 'Novel approaches to preventing perinatal death and disability from birth asphyxia', \$2,174,514.

Prof Vicki Flenady, Centres of Research Excellence, 'Centre of Research Excellence in Stillbirth' \$2,500,000.

Prof Allison Pettit, Ideas grant, 'Increasing hematopoietic stem cell niches post transplantation through enhancing bone marrow macrophage resilience and regeneration mechanisms', \$935,616.

Dr Jake Gratten, Ideas grant, 'Understanding the aetiology of Parkinson's disease through integrative cellular genomics', \$837,064.

Dr Katharine Irvine, Ideas grant, 'Macrophage-driven lipid metabolism in health and disease – mechanisms and therapeutic opportunities', \$656,972.

Medical Research Futures Fund

A/Prof Phillip Good, 'Medicinal Cannabis (MedCan 3) - randomised, multicentre, double blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer' \$1,526,796.

The University of Queensland (UQ)

Dr Jodi Saunus, Research Support Package, 'Development of new diagnostic and therapeutic agents for breast cancer and generate new knowledge about the mechanisms of metastasis', \$124,378.

Dr Danielle Borg, Research Support Package, 'Examining the role of the microbiome in child obesity', \$105,341.

Dr Katie Brooker, Research Support Package, 'Development and implementation of a health assessment tool for Autistic people with intellectual disability' \$90,180.

Dr Amelia Fotheringham, Research Support Package, 'Examining new therapies for the prevention of type 1 diabetes', \$90,180.

Dr Camille Guillerey, Foundation Research Excellence Award, 'Unleashing innate immunity against Leukaemia', \$63,467.

A/Prof Sumaira Hasnain, AID project seed fund, 'Evaluation of the levels of IL-22 in children with respiratory infection', \$50,000.

Dr Yu-Chen (Enya) Chen, Research Support Package, \$45,090.

Dr Joshua Tobin, Research Support Package, \$45,090.

Dr Lena Batoon, Research Support Package, \$45,090.

Dr Md Moniruzzaman, Research Support Package, \$45,090.

A/Prof Sumaira Hasnain, Australian Infectious Diseases Centre Near-Miss Award, 'Targeting Immunopathology in Chronic Infectious and Inflammatory Diseases', \$40,000.

Translational Research Institute (TRI)

Dr Kavita Bisht, Leading Innovations through New Collaborations grant, 'Identifying mechanism and new therapies to treat anaemia of inflammation in Inflammatory Bowel Diseases' \$50,000.

Dr Reuben Beer, Leading Innovations through New Collaborations grant, 'Linking Advanced Neuroimaging, Disease State and Clinical Measures in Multiple Sclerosis: A multi-disciplinary and multi-institutional research approach', \$50,000.

Dr Sandra Richardson, Leading Innovations through New Collaborations grant, 'DNA methylation in circulating free fetal DNA: A potential biomarker to predict fetal growth', \$50,000.

Overseas Agencies

A/Prof Jake Begun, US Department of Defense, 'Drugs from Bugs: Developing New Inflammatory Bowel Disease Drugs from Gut Bacteria-Derived Bioactives', \$2,323,910 (AUD).

Prof Jean-Pierre Levesque, US Department of Defense, 'Investigate the mechanisms of neurogenic heterotopic ossifications', \$1,927,892 (AUD).

A/Prof Jake Begun, Pfizer, 'Study of Tofacitinib for the treatment of chronic Pouchitis ? capital (STOPit)', \$56,232 USD.

Prof Brian Gabrielli, Melanoma Research Alliance, 'Enhancing tumour immune detection by targeting replication stress', \$373,900 USD.

Dr Josh Tobin, American Society of Hematology Global Fellowship, 'Applying Measures of Immune-Fitness in Follicular Lymphoma', \$150,000 USD

Industry, Government, and other funding

Dr Jake Gratten, Autism Speaks, 'A Big Data Approach in Understanding Restricted and Repetitive Behaviours in Autism: Linking Taxonomy to Etiology', \$5,000.

Prof Geoff Faulkner, Cancer Australia, 'Long-read genetic and epigenetic profiling in lung cancer for precision medicine', \$567,596.

Dr Camille Guillerey, Cancer Australia, 'Utilising cord blood-derived Natural Killer cells to prevent post-transplant relapse in Childhood Leukaemia', \$198,742.

A/Prof Paul Dawson, Cerebral Palsy Alliance, 'SuPreme Study: towards a sulphate therapy to reduce the rate of cerebral palsy among preterm' \$250,000.

Prof Sailesh Kumar, Cerebral Palsy Alliance, 'Predicting and preventing fetal compromise in labour for small-for-gestational-age infants', \$75,000.

Dr Dhanisha Jhaveri, Dementia Australia, 'Cholinergic regulation of adult hippocampal neurogenesis and cognitive functions', \$75,000.

Prof Vicki Flenady, Department of Health Australia, 'Adaptation and Cultural Specification of Safer Baby Bundle Health (20/21-E21-4084)', \$2,131,443.

Dr Helen Barrett, Diabetes Australia Research Program, 'Assessing hyperglycaemia in women pregnant after bariatric surgery', \$60,000.

A/Prof Katharina Ronacher, Diabetes Australia Research Program, 'Harnessing Oxidised Cholesterols to Reduce Susceptibility to COVID-19 in Obesity and Diabetes', \$70,000.

Prof Sailesh Kumar, Ferring Research Institute, 'Machine learning and artificial intelligence techniques to develop predictive models for late gestation adverse perinatal outcomes', \$48,489.

Prof Jean-Pierre Levesque, FibroGen, 'Quantify the effect of FG-6874 on hematopoietic stem cell mobilization and transplantation', \$193,907.

A/Prof Sumaira Hasnain, Gastroenterological Society of Australia (GESA) Dr Falk Pharma Research Grant, 'Can Interleukin-24 be Targeted to Reduce Fibrosis in Inflammatory Bowel Disease?', \$30,000.

Dr Emi Khoo, Gastroenterological Society of Australia, 'Celtrion IBD Fellowship', \$30,000.

Dr Yonghua Sheng, Gastroenterological Society of Australia, 'Targeting MUC1 Cell Surface Mucin to sensitise colorectal cancer to therapy', \$30,000.

Dr Yonghua Sheng, Gastroenterological Society of Australia, 'Examining the Therapeutic Potential of MUC1 Inhibition in Inflammatory Bowel Disease', \$30,000.

Dr Ran Wang, Gastroenterological Society of Australia, 'Development of a Novel Inhibitor of IL-23p19 for Inflammatory Bowel Disease', \$22,727.

A/Prof Jake Begun, Janssen Cilag, 'Development of an Australian intestinal ultrasound (IUS) education', \$50,000.

A/Prof Sumaira Hasnain, Jetra Therapeutics, 'Development of IL-22 fusion proteins for treatment of fatty liver disease', \$300,034.

Prof Josephine Forbes, Juvenile Diabetes Research Foundation, 'Innovative delivery methods for the biologic soluble RAGE to prevent Type 1', \$600,084.

Dr Sahar Keshvari, The Liver Foundation - Professor Pauline Hall Research Fellowship, 'Therapeutic Application of Macrophage Colony Stimulating Factor (CSF1) for Liver Regeneration', \$120,000.

Dr Tegan Triggs, Royal Australian and New Zealand College of Obstetricians and Gynaecologists Women's Health Foundation, 'Reducing emergency caesarean birth for fetal distress in women with small or poorly grown infants using Sildenafil Citrate – The RidStress 2 Randomised Controlled Trial', \$60,000.

Prof Vicki Flenady, Queensland Government, 'Improve 2', \$63,060.

Dr Josh Tobin, Snowdome Fellowship, 'The Development of Biomarker-Directed Immunotherapy in Advanced Stage Follicular Lymphoma Patients', \$200,000.

Dr Christine Andrews, Stillbirth Foundation, 'Improving the capacity of researchers and bereaved parents to co-design and translate research together: "A Guide to Research for Bereaved Parents"', \$19,673.
Ms Siobhan Loughnan, Stillbirth Foundation, 'Caring for parents in a subsequent pregnancy after stillbirth: Availability of services across Australia and a social return on investment analysis', \$47,858.


Publications

Knowledge dissemination via peer-reviewed publication underpins research and health care advancements. Publications are currency in research and the number, quality, reach and impact are key measures used to rank a researcher's calibre.

In 2021 a total of 587 publications were authored by Mater and Mater-affiliated researchers; this number is a record 34% increase in publications compared to 2020. More than half (322) of these publications were published in the highest ranked journals for their field (top tier, also labelled Q1) after vigorous peer review processes.

2021 Publications across all programs

Total number of publications = 587



■ Mother and Baby ■ Cancer ■ Neuroscience ■ Chronic and Integrated Care ■ Health Care Delivery and Innovation

% Percentage of Quartile 1 (Q1) publications for each Program

Publications are assigned to a Program based on content (title/abstract) versus researcher primary affiliation

Publications in 2021 (01 Jan – 31 Dec)

*Arranged in ascending order by author last name

1. Adams, A.G., et al., A comprehensive assessment of poststroke social cognitive function. *Neuropsychology*, 2021. 35(5): p. 556-567.
2. Albertella, L., B. Farrant, and S. Denny, "Improving the quality of care for adolescents and young adults on an adult medical ward". *Intern Med J*, 2021.
3. Alharbi, M., et al., Extracellular Vesicle Transmission of Chemoresistance to Ovarian Cancer Cells Is Associated with Hypoxia-Induced Expression of Glycolytic Pathway Proteins, and Prediction of Epithelial Ovarian Cancer Disease Recurrence. *Cancers (Basel)*, 2021. 13(14).
4. Alif, S.M., et al., Cancer and mortality in coal mine workers: a systematic review and meta-analysis. *Occup Environ Med*, 2021.
5. Alisjahbana, B., et al., Screening diabetes mellitus patients for pulmonary tuberculosis: A multisite study in Indonesia, Peru, Romania and South Africa. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 2021. 115(6): p. 634-643.
6. Alshyyab, M.A., et al., Strategies and interventions for improving safety culture in Australian Emergency Departments: A modified Delphi study. *Int J Health Plann Manage*, 2021.
7. Alwash, S.M., H.D. McIntyre, and A. Mamun, The association of general obesity, central obesity and visceral body fat with the risk of gestational diabetes mellitus: Evidence from a systematic review and meta-analysis. *Obes Res Clin Pract*, 2021. 15(5): p. 425-430.
8. An, Y.K., Common mistakes with steroids. *J Gastroenterol Hepatol*, 2021. 36 Suppl 1: p. 30-31.
9. Andrews, C., et al., Evaluation of an online education module designed to reduce stillbirth. *Aust N Z J Obstet Gynaecol*, 2021.
10. Ang, C.W., et al., Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles. *ACS Biomater Sci Eng*, 2021.
11. Axelsen, S.M., et al., Intrahepatic cholestasis of pregnancy: Association with glycaemic control in gestational diabetes. *Diabet Med*, 2021: p. e14574.
12. Bailey, A., et al., Absolute cardiovascular disease risk score and pharmacotherapy at the time of admission in patients presenting with acute coronary syndrome due to coronary artery disease in a single Australian tertiary centre: a cross-sectional study. *BMJ Open*, 2021. 11(2): p. e038868.
13. Balaam, S., et al., Alcohol and Breast Cancer: Results From the Women's Wellness After Cancer Program Randomized Controlled Trial. *Cancer Nurs*, 2021.
14. Banun, V.J., et al., Protein Nanoparticles for Enhanced Oral Delivery of Coenzyme-Q10: in Vitro and in Silico Studies. *ACS Biomater Sci Eng*, 2021.
15. Barrett, H.L., et al., Capillary Triglycerides in Late Pregnancy-Challenging to Measure, Hard to Interpret: A Cohort Study of Practicality. *Nutrients*, 2021. 13(4).
16. Bartho, L.A., et al., Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies. *Placenta*, 2021. 112: p. 162-171.
17. Batoon, L. and L.K. McCauley, Cross Talk Between Macrophages and Cancer Cells in the Bone Metastatic Environment. *Front Endocrinol (Lausanne)*, 2021. 12: p. 763846.
18. Batoon, L., et al., Osteal macrophages support osteoclast-mediated resorption and contribute to bone pathology in a postmenopausal osteoporosis mouse model. *J Bone Miner Res*, 2021. 36(11): p. 2214-2228.
19. Batoon, L., et al., Treatment with a long-acting chimeric CSF1 molecule enhances fracture healing of healthy and osteoporotic bones. *Biomaterials*, 2021. 275: p. 120936.
20. Baumann-Birkbeck, L., et al., Can a virtual microbiology simulation be as effective as the traditional Wetlab for pharmacy student education? *BMC Med Educ*, 2021. 21(1): p. 583.
21. Bayoumy, A.B., et al., Advances in Thiopurine Drug Delivery: The Current State-of-the-Art. *Eur J Drug Metab Pharmacokinet*, 2021.
22. Beck, S., et al., From Other Journals. *EMA - Emergency Medicine Australasia*, 2021. 33(2): p. 392-394.

23. Bednarska, K., et al., Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. *Blood Reviews*, 2021.
24. Beer, R., et al., A case of IVIg responsive paraneoplastic SOX1 peripheral neuropathy in a male with breast carcinoma. *J Neuroimmunol*, 2021. 352: p. 577492.
25. Begun, J., So many therapies-So little data: How to choose? Session two summary. *J Gastroenterol Hepatol*, 2021. 36 Suppl 1: p. 14-15.
26. Beilby, H., et al., Cost-effectiveness of gestational diabetes screening including prevention of type 2 diabetes: application of the GeDiForCE model in Australia. *J Matern Fetal Neonatal Med*, 2021: p. 1-8.
27. Beker, F., et al., Effects on Growth of Smell and Taste of Milk During Tube Feeding of Preterm Infants: A Randomized Clinical Trial. *JAMA Pediatr*, 2021. 175(11): p. 1115-1123.
28. Bergström, L. and J.A. Cichero, Dysphagia management: Does structured training improve the validity and reliability of cervical auscultation? *Int J Speech Lang Pathol*, 2021: p. 1-11.
29. Beringer, M., et al., Nutritional adequacy and the role of supplements in the diets of Indigenous Australian women during pregnancy. *Midwifery*, 2021. 93: p. 102886.
30. Berkhout, A., et al., Herpes Simplex Virus Infection in Infants: 13 Year Evaluation (2005-2017) of Laboratory Confirmed Cases in Queensland, Australia. *Pediatric Infectious Disease Journal*, 2021: p. 209-214.
31. Bernardes, C.M., et al., Disparities in Unmet Needs in Indigenous and Non-Indigenous Australians with Cirrhosis: An Exploratory Study. *Patient Prefer Adherence*, 2021. 15: p. 2649-2658.
32. Bhamidipaty-Pelosi, S., et al., The risk of recurrent small-for-gestational-age infants at term is dependent on the number of previously affected births. *Am J Obstet Gynecol*, 2021.
33. Bhide, A., et al., ISUOG Practice Guidelines (updated): use of Doppler velocimetry in obstetrics. *Ultrasound Obstet Gynecol*, 2021. 58(2): p. 331-339.
34. Bhurani, M., et al., Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study. *Leuk Lymphoma*, 2021. 62(2): p. 330-336.
35. Bicknell, B., et al., Modifying the Microbiome as a Potential Mechanism of Photobiomodulation: A Case Report. *Photobiomodul Photomed Laser Surg*, 2021.
36. Bish, M.R., et al., Relationship between obesity and lower rates of breast feeding initiation in regional Victoria, Australia: an 8-year retrospective panel study. *BMJ Open*, 2021. 11(2): p. e044884.
37. Bisht, K., et al., Oncostatin M regulates hematopoietic stem cell (HSC) niches in the bone marrow to restrict HSC mobilization. *Leukemia*, 2021.
38. Blackmore, D.G., et al., An exercise "sweet spot" reverses cognitive deficits of aging by growth-hormone-induced neurogenesis. *iScience*, 2021. 24(11): p. 103275.
39. Bokern, M.P., et al., Factors Associated with Asthma Exacerbations During Pregnancy. *J Allergy Clin Immunol Pract*, 2021.
40. Bongay, L. and K. Kynoch, Improving care for thalassemia patients in line with best practice standards at a tertiary referral cancer care center. *JBI Evid Implement*, 2021.
41. Boo, G., A. Ji, and A. Morton, Diabetic ketoacidosis and unilateral thigh pain. *Emerg Med Australas*, 2021.
42. Borg, D., et al., Queensland Family Cohort: a study protocol. *BMJ Open*, 2021. 11(6): p. e044463.
43. Borg, D.J., et al., Short Duration Alagebrium Chloride Therapy Prediabetes Does Not Inhibit Progression to Autoimmune Diabetes in an Experimental Model. *Metabolites*, 2021. 11(7).
44. Bossuyt, S.N.V., et al., Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations. *Hum Mol Genet*, 2021.
45. Bottomley, A., et al., Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. *The Lancet Oncology*, 2021. 22(5): p. 655-664.
46. Boyd, G.E., et al., Caesarean section improves neonatal outcomes only from 24+0 weeks for periviable breech but not for cephalic infants. *J Matern Fetal Neonatal Med*, 2021. 34(4): p. 599-605.

47. Bradshaw, P., et al., 'Autistic' or 'with autism'? Why the way general practitioners view and talk about autism matters. *Australian journal of general practice*, 2021. 50(3): p. 104-108.
48. Branjerdporn, G., et al., Infant sensory patterns: associations with previous perinatal loss, maternal-foetal attachment and postnatal maternal sensory patterns. *Irish Journal of Occupational Therapy*, 2021. 49(1): p. 3-10.
49. Branjerdporn, G., et al., Maternal–Fetal Attachment: Associations with Maternal Sensory Processing, Adult Attachment, Distress and Perinatal Loss. *Journal of Child and Family Studies*, 2021. 30(2): p. 528-541.
50. Brischetto, A., J. Schooneveldt, and S. Schlebusch, Evaluation of direct antimicrobial susceptibility testing using positive blood culture broth in an Australian laboratory. *Pathology*, 2021.
51. Bromley, P., et al., Examining workplace-based education strategies for the 21st century neonatal nurse: Literature review. *Journal of Neonatal Nursing*, 2021. 27(6): p. 396-401.
52. Bromley, P., et al., Survey: Is workplace-based learning meeting the needs of the 21st century neonatal nurse in Australia? *Journal of Neonatal Nursing*, 2021.
53. Broom, E., et al., Management of Fetal Supraventricular Tachycardia: Case Series from a Tertiary Perinatal Cardiac Center. *Fetal Diagn Ther*, 2021: p. 1-7.
54. Brown, H., A. Griffin, and J. Muir, Concordance between patient-identified concerns and skin cancer diagnosis - an observational cross-sectional study. *Australas J Dermatol*, 2021.
55. Brown, H., T. Pitney, and J. Muir, Base Transection with Shaves: An Avoidable Shortcoming : Reply to Impact of Shave Biopsy on Diagnosis and Management of Cutaneous Melanoma: A Systematic Review and Meta-analysis. *Ann Surg Oncol*, 2021.
56. Browne, J.J., et al., Otopathogen interactions in the nasopharynx of children, and the predictive value of nasopharyngeal aspirate culture for the aetiology of upper respiratory infections. *Journal of Paediatrics and Child Health*, 2021.
57. Buckle, I. and C. Guillerey, Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. *Cancers (Basel)*, 2021. 13(17).
58. Bullock-Saxton, J., A. Lehn, and E.L. Laakso, Exploring the Effect of Combined Transcranial and Intra-Oral Photobiomodulation Therapy Over a Four-Week Period on Physical and Cognitive Outcome Measures for People with Parkinson's Disease: A Randomized Double-Blind Placebo-Controlled Pilot Study. *Journal of Alzheimer's Disease*, 2021.
59. Burgess, L., et al., The effectiveness of nurse-initiated interventions in the Emergency Department: A systematic review. *Australas Emerg Care*, 2021.
60. Burgess, L., G. Ray-Barruel, and K. Kynoch, Association between emergency department length of stay and patient outcomes: A systematic review. *Res Nurs Health*, 2021.
61. Burnard, D., et al., Burkholderia pseudomallei clinical isolates are highly susceptible in vitro to cefiderocol, a siderophore cephalosporin. *Antimicrobial Agents and Chemotherapy*, 2021. 65(2).
62. Button, E., et al., Prospective cohort study of an Australian cancer care services-led model of emergent care. *Australian Health Review*, 2021. 45(5): p. 613-621.
63. Byford, S., S. Janssens, and R. Cook, Implementing the transvaginal ultrasound simulation training (TRUSST) programme for obstetric registrars. *Adv Simul (Lond)*, 2021. 6(1): p. 1.
64. Callander, E., et al., Inequitable use of health services for Indigenous mothers who experience stillbirth in Australia. *Birth*, 2021.
65. Cao, P., et al., Enhanced Mucosal Transport of Polysaccharide–Calcium Phosphate Nanocomposites for Oral Vaccination. *ACS Applied Bio Materials*, 2021. 4(11): p. 7865-7878.
66. Cao, Y., et al., Nanocarriers for oral delivery of biologics: small carriers for big payloads. *Trends Pharmacol Sci*, 2021. 42(11): p. 957-972.
67. Cardoso, D., et al., Fresno test to measure evidence-based practice knowledge and skills for Portuguese undergraduate nursing students: A translation and adaptation study. *Nurse Educ Today*, 2021. 97: p. 104671.

68. Cardoso, D., et al., Nursing educators' and undergraduate nursing students' beliefs and perceptions on evidence-based practice, evidence implementation, organizational readiness and culture: An exploratory cross-sectional study. *Nurse Educ Pract*, 2021. 54: p. 103122.
69. Cardoso, D., et al., The Effectiveness of an Evidence-Based Practice (EBP) Educational Program on Undergraduate Nursing Students' EBP Knowledge and Skills: A Cluster Randomized Control Trial. *Int J Environ Res Public Health*, 2021. 18(1).
70. Cereda, E., et al., Recovery Focused Nutritional Therapy across the Continuum of Care: Learning from COVID-19. *Nutrients*, 2021. 13(9).
71. Cervenka, M.C., et al., International Recommendations for the Management of Adults Treated With Ketogenic Diet Therapies. *Neurol Clin Pract*, 2021. 11(5): p. 385-397.
72. Chaboyer, W., et al., Incidence and predictors of surgical site infection in women who are obese and give birth by elective caesarean section: A secondary analysis. *Aust N Z J Obstet Gynaecol*, 2021.
73. Chada, R.R., et al., Association between nutrition delivery, modified Nutrition Risk in Critically Ill score, and 28-day mortality. *Nutrition in Clinical Practice*, 2021.
74. Chada, R.R., et al., Tailoring nutrition therapy amid the COVID-19 pandemic: Does it work? *Clin Nutr ESPEN*, 2021. 45: p. 381-388.
75. Chamunyonga, C., et al., Advancing leadership in medical radiation sciences: Incorporating systematic leadership education in pre-registration curricula. *J Med Imaging Radiat Sci*, 2021. 52(4): p. 499-504.
76. Chan Pei Loon, J., et al., Eustachian valve endocarditis: Case report and literature review. *Australas J Ultrasound Med*, 2018. 21(1): p. 29-35.
77. Chan, A., et al., Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. *Asia Pac J Clin Oncol*, 2021.
78. Chan, F., et al., Voltage-gated potassium channel blanket testing in first-episode psychosis: Diagnostic nihilism? *Aust N Z J Psychiatry*, 2021: p. 4867420983454.
79. Chan, L., et al., Evaluation of Movements Matter: A social media and hospital-based campaign aimed at raising awareness of decreased fetal movements. *Aust N Z J Obstet Gynaecol*, 2021.
80. Chandrashekar, M., et al., Sodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications. *Int J Urol*, 2021.
81. Chaowawanit, W., et al., Retrospective review of sentinel lymph node mapping in endometrial cancer using indocyanine green and near infra-red fluorescence imaging during minimally invasive surgery. *European Journal of Gynaecological Oncology*, 2021. 42(4): p. 694-702.
82. Chappell, K.J., et al., Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. *Lancet Infect Dis*, 2021.
83. Chawla, J., et al., Cognitive parameters in children with mild obstructive sleep disordered breathing. *Sleep Breath*, 2021.
84. Chen, H., et al., Too little, too late: Palliation and end-stage liver disease. *J Gastroenterol Hepatol*, 2021.
85. Chevallier, M., et al., Mortality and significant neurosensory impairment in preterm infants: an international comparison. *Arch Dis Child Fetal Neonatal Ed*, 2021.
86. Chi, C., et al., Early Gut Microbiota Colonisation of Premature Infants Fed with Breastmilk or Formula with or without Probiotics: A Cohort Study. *Nutrients*, 2021. 13(11).
87. Chin, X., A. Nicol, and J.Y. Ng, Mesh migration mimicking sigmoid diverticulitis. *ANZ J Surg*, 2021.
88. Christian, K., et al., A survey of early-career researchers in Australia. *Elife*, 2021. 10.
89. Chughlay, M.F., et al., Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults. *Antimicrob Agents Chemother*, 2021: p. Aac0158421.
90. Cilliers, K., et al., Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response. *Tuberculosis (Edinb)*, 2021. 128: p. 102082.

91. Clark, P.J., Eliminating hepatitis C in Australia needs informed patients and enabled GPs. *Med J Aust*, 2021. 215(7): p. 318-319.
92. Clarke, L., et al., Response to treatment in NMOSD: the Australasian experience. *Multiple Sclerosis and Related Disorders*, 2021.
93. Clifton, V.L., et al., Neonatal death is a major concern for Indigenous women with asthma during pregnancy and could be prevented with better models of care. *Aust N Z J Obstet Gynaecol*, 2021.
94. Collins, P.F., et al., Effective nutrition support for patients with chronic obstructive pulmonary disease: managing malnutrition in primary care. *Br J Gen Pract*, 2021. 71(710): p. 427-428.
95. Conroy, J.N., D.J. Jhaveri, and E.J. Coulson, Fast-Trk(B)ing the mechanism of antidepressants. *Neuron*, 2021. 109(10): p. 1593-1595.
96. Cossar, R.D., et al., Emergency department presentations in the first weeks following release from prison among men with a history of injecting drug use in Victoria, Australia: A prospective cohort study. *Int J Drug Policy*, 2021. 101: p. 103532.
97. Coulthard, L.G., et al., Growth of Intramedullary Spinal Cord Dermoid Cyst from a Congenital Thoracic Dermal Sinus Tract after Negative Screening Ultrasound Imaging. *Pediatr Neurosurg*, 2021: p. 1-6.
98. Couper, J.J., et al., Determinants of Cardiovascular Risk in 7000 Youth With Type 1 Diabetes in the Australasian Diabetes Data Network. *The Journal of clinical endocrinology and metabolism*, 2021. 106(1): p. 133-142.
99. Crawford, K.L., et al., Survival Analysis of Training Methodologies and Other Risk Factors for Musculoskeletal Injury in 2-Year-Old Thoroughbred Racehorses in Queensland, Australia. *Front Vet Sci*, 2021. 8: p. 698298.
100. Crichton, M., et al., "It's natural so it shouldn't hurt me": Chemotherapy patients' perspectives, experiences, and sources of information of complementary and alternative medicines. *Complement Ther Clin Pract*, 2021. 43: p. 101362.
101. Cuda, T.J., et al., Preclinical Molecular PET-CT Imaging Targeting CDCP1 in Colorectal Cancer. *Contrast Media Mol Imaging*, 2021. 2021: p. 3153278.
102. Dall'Asta, A. and S. Kumar, Prelabor and intrapartum Doppler ultrasound to predict fetal compromise. *Am J Obstet Gynecol MFM*, 2021: p. 100479.
103. Damhuis, S.E., et al., The CErebro Placental RAtio as indicator for delivery following perception of reduced fetal movements, protocol for an international cluster randomised clinical trial; the CEPRA study. *BMC Pregnancy Childbirth*, 2021. 21(1): p. 285.
104. Das, J., et al., Maternal asthma during pregnancy and extremes of body mass index increase the risk of perinatal mortality: a retrospective cohort study. *J Asthma*, 2021: p. 1-9.
105. Davidson, S.J., et al., Probiotics for preventing gestational diabetes. *Cochrane Database Syst Rev*, 2021. 4(4): p. Cd009951.
106. Davies, J.M., et al., Adhesion to E-selectin primes macrophages for activation through AKT and mTOR. *Immunol Cell Biol*, 2021.
107. Davies-Tuck, M., et al., Interventions relating to fetal movements for improving pregnancy outcomes. *Cochrane Database of Systematic Reviews*, 2021. 2021(7).
108. de Alwis, N., et al., LOX-1 expression is reduced in placenta from pregnancies complicated by preeclampsia and in hypoxic cytotrophoblast. *Pregnancy Hypertens*, 2021. 25: p. 255-261.
109. de Alwis, N., et al., NR4A2 expression is not altered in placentas from cases of growth restriction or preeclampsia, but is reduced in hypoxic cytotrophoblast. *Sci Rep*, 2021. 11(1): p. 20670.
110. De Gregorio, M., et al., Higher Anti-tumor Necrosis Factor- α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas. *Clin Gastroenterol Hepatol*, 2021.
111. Debaud, C., et al., Local and Systemic Factors Drive Ectopic Osteogenesis in Regenerating Muscles of Spinal-Cord-Injured Mice in a Lesion-Level-Dependent Manner. *J Neurotrauma*, 2021. 38(15): p. 2162-2175.

112. Delaforce, A., et al., A Theoretically Informed Approach to Support the Implementation of Pre-Operative Anemia and Iron Deficiency Screening, Evaluation, and Management Pathways: Protocol for a Type Two Hybrid-Effectiveness Study. *J Multidiscip Healthc*, 2021. 14: p. 1037-1044.
113. Deprest, J.A., et al., Randomized Trial of Fetal Surgery for Moderate Left Diaphragmatic Hernia. *N Engl J Med*, 2021. 385(2): p. 119-129.
114. Desmyth, K., et al., Refugee health nursing. *J Adv Nurs*, 2021.
115. Dignass, A.U., et al., Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. *Scand J Gastroenterol*, 2021: p. 1-8.
116. Doi, S.A.R., et al., Unifying the diagnosis of gestational diabetes mellitus: Introducing the NPRP criteria. *Prim Care Diabetes*, 2021.
117. Doola, R., et al., Diabetes-specific formulae versus standard formulae as enteral nutrition to treat hyperglycemia in critically ill patients: Protocol for a randomized controlled feasibility trial. *JMIR Research Protocols*, 2018. 7(4).
118. Doola, R., et al., The impact of a modified carbohydrate formula, and its constituents, on glycaemic control and inflammatory markers: A nested mechanistic sub-study. *J Hum Nutr Diet*, 2021.
119. Drever, N., et al., Reply to "Caesarean scar pregnancy: Look at a leopard through a tube". *Aust N Z J Obstet Gynaecol*, 2021. 61(1): p. E4-e5.
120. Drummond, K.D., et al., Hippocampal neurogenesis mediates sex-specific effects of social isolation and exercise on fear extinction in adolescence. *Neurobiol Stress*, 2021. 15: p. 100367.
121. Edwards, C., et al., Changes in placental elastography in the third trimester - Analysis using a linear mixed effect model. *Placenta*, 2021. 114: p. 83-89.
122. Edwards, C., et al., Intra-system reliability assessment of 2-dimensional shear wave elastography. *Applied Sciences (Switzerland)*, 2021. 11(7).
123. Elliott, C., et al., Early Moves: a protocol for a population-based prospective cohort study to establish general movements as an early biomarker of cognitive impairment in infants. *BMJ Open*, 2021. 11(4): p. e041695.
124. Elshaer, D., et al., Facile synthesis of dendrimer like mesoporous silica nanoparticles to enhance targeted delivery of interleukin-22. *Biomater Sci*, 2021. 9(22): p. 7402-7411.
125. Ewais, T., et al., Mindfulness based cognitive therapy for youth with inflammatory bowel disease and depression - Findings from a pilot randomised controlled trial. *J Psychosom Res*, 2021. 149: p. 110594.
126. Ewing, A.D., et al., Microdeletion of 9q22.3: A patient with minimal deletion size associated with a severe phenotype. *Am J Med Genet A*, 2021. 185(7): p. 2070-2083.
127. Faulkner, G.J., The evolving gene regulatory landscape-a tinkerer of complex creatures. *Genome Biol*, 2021. 22(1): p. 199.
128. Fernando, M., et al., Dysregulated G2 phase checkpoint recovery pathway reduces DNA repair efficiency and increases chromosomal instability in a wide range of tumours. *Oncogenesis*, 2021. 10(5): p. 41.
129. Fischer, A., et al., Evaluation of a nurse practitioner role within a specialist palliative care service in Australia. *Progress in Palliative Care*, 2021.
130. Fitzallen, G.C., et al., Anxiety and Depressive Disorders in Children Born Preterm: A Meta-Analysis. *J Dev Behav Pediatr*, 2021.
131. Fjeldsoe, B.S., et al., Dose and engagement during an extended contact physical activity and dietary behavior change intervention delivered via tailored text messaging: exploring relationships with behavioral outcomes. *Int J Behav Nutr Phys Act*, 2021. 18(1): p. 119.
132. Flanagan, E., et al., Ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero. *Aliment Pharmacol Ther*, 2021.
133. Flavell, J. and P.J. Nestor, A Systematic Review of Apathy and Depression in Progressive Supranuclear Palsy. *J Geriatr Psychiatry Neurol*, 2021: p. 891988721993545.
134. Flenady, V., et al., Making every birth count: Outcomes of a perinatal mortality audit program. *Aust N Z J Obstet Gynaecol*, 2021. 61(4): p. 540-547.

135. Flenady, V., et al., My Baby's Movements: a stepped-wedge cluster-randomised controlled trial of a fetal movement awareness intervention to reduce stillbirths. *Bjog*, 2021.
136. Flynn, N., et al., The sustainability of upper limb robotic therapy for stroke survivors in an inpatient rehabilitation setting. *Disabil Rehabil*, 2021: p. 1-6.
137. Forbes, J.M., et al., Advanced glycation end products as predictors of renal function in youth with type 1 diabetes. *Sci Rep*, 2021. 11(1): p. 9422.
138. Forbes, J.M., et al., T-Cell Expression and Release of Kidney Injury Molecule-1 in Response to Glucose Variations Initiates Kidney Injury in Early Diabetes. *Diabetes*, 2021. 70(8): p. 1754-1766.
139. Fotheringham, A.K., et al., Kidney disease risk factors do not explain impacts of low dietary protein on kidney function and structure. *iScience*, 2021. 24(11): p. 103308.
140. Franklin, D., et al., High flow in children with respiratory failure: A randomised controlled pilot trial - A paediatric acute respiratory intervention study. *J Paediatr Child Health*, 2021. 57(2): p. 273-281.
141. Freeman, C.R., et al., Reducing Medical Admissions and Presentations Into Hospital through Optimising Medicines (REMAIN HOME): a stepped wedge, cluster randomised controlled trial. *Med J Aust*, 2021.
142. Fuchs, T.L., et al., Expanding the clinicopathological spectrum of succinate dehydrogenase-deficient renal cell carcinoma with a focus on variant morphologies: a study of 62 new tumors in 59 patients. *Mod Pathol*, 2021.
143. Futrega, K., et al., A single day of TGF- β 1 exposure activates chondrogenic and hypertrophic differentiation pathways in bone marrow-derived stromal cells. *Commun Biol*, 2021. 4(1): p. 29.
144. Futrega, K., et al., Characterisation of ovine bone marrow-derived stromal cells (oBMSC) and evaluation of chondrogenically induced micro-pellets for cartilage tissue repair in vivo. *Stem Cell Res Ther*, 2021. 12(1): p. 26.
145. Gallagher, G., et al., Impact of simulation training on decision to delivery interval in cord prolapse. *BMJ Simulation and Technology Enhanced Learning*, 2021. 7(6): p. 543-547.
146. Gallo, L.A., et al., A decline in planned, but not spontaneous, preterm birth rates in a large Australian tertiary maternity centre during COVID-19 mitigation measures. *Aust N Z J Obstet Gynaecol*, 2021.
147. Gallo, L.A., et al., Adherence to Dietary and Physical Activity Guidelines in Australian Undergraduate Biomedical Students and Associations with Body Composition and Metabolic Health: A Cross-Sectional Study. *Nutrients*, 2021. 13(10).
148. Gandhi, M.K., et al., EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. *Blood*, 2021. 137(11): p. 1468-1477.
149. Gannon, B., D. Jayawardana, and V. Clifton, Descriptive Data Analysis of Inequality of Economic Opportunity using the Queensland Family Cohort Pilot Study. *Australian Economic Review*, 2021. 54(3): p. 398-405.
150. Gardiner, F.W., et al., Characteristics and in-hospital outcomes of patients requiring aeromedical retrieval for pregnancy, compared to non-retrieved metropolitan cohorts. *Aust N Z J Obstet Gynaecol*, 2021.
151. Garg, M., et al., Tumour gene expression signature in primary melanoma predicts long-term outcomes. *Nat Commun*, 2021. 12(1): p. 1137.
152. Gassiep, I., et al., Diagnosis of melioidosis: the role of molecular techniques. *Future Microbiol*, 2021.
153. Gassiep, I., et al., Laboratory Safety: Handling *Burkholderia pseudomallei* Isolates without a Biosafety Cabinet. *J Clin Microbiol*, 2021. 59(7): p. e0042421.
154. Gassiep, I., et al., Melioidosis: Laboratory Investigations and Association with Patient Outcomes. *Am J Trop Med Hyg*, 2021. 106(1): p. 54-59.
155. Gassiep, I., et al., The epidemiology of melioidosis in Townsville, Australia. *Trans R Soc Trop Med Hyg*, 2021.
156. Gažová, I., et al., CRISPR-Cas9 Editing of Human Histone Deubiquitinase Gene USP16 in Human Monocytic Leukemia Cell Line THP-1. *Frontiers in Cell and Developmental Biology*, 2021. 9.
157. Geffen, S. and N. Chiang, Successful Treatment of Stiff Person Syndrome with Intrathecal Baclofen. *J Rehabil Med Clin Commun*, 2019. 2: p. 1000016.

158. Gehlert, J. and A. Morton, Eplerenone as a treatment for resistant hypertension in pregnancy. *Obstet Med*, 2021. 14(1): p. 35-38.
159. Gehue, L.J., et al., Piloting the 'Youth Early-intervention Study' ('YES'): Preliminary functional outcomes of a randomized controlled trial targeting social participation and physical well-being in young people with emerging mental disorders. *Journal of Affective Disorders*, 2021. 280: p. 180-188.
160. Geraerds, A., et al., Cost impact of procalcitonin-guided decision making on duration of antibiotic therapy for suspected early-onset sepsis in neonates. *Crit Care*, 2021. 25(1): p. 367.
161. Geraldine Moses, A.M., The safety of commonly used vitamins and minerals. *Australian Prescriber*, 2021. 44(4): p. 119-123.
162. Gerhardy, B. and S. Bowler, Piperacillin-tazobactam-induced haemolytic anaemia after multiple courses of therapy. *Intern Med J*, 2021. 51(3): p. 458.
163. Ghoniem, K., et al., Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study. *Gynecol Oncol*, 2021. 162(3): p. 590-598.
164. Gibson, A.L.F., et al., Coming to Consensus: What Defines Deep Partial Thickness Burn Injuries in Porcine Models? *J Burn Care Res*, 2021. 42(1): p. 98-109.
165. Gillespie, B.M., et al., Closed incision negative pressure wound therapy versus standard dressings in obese women undergoing caesarean section: multicentre parallel group randomised controlled trial. *The BMJ*, 2021. 373: p. n893.
166. Gillespie, B.M., et al., Effect of negative-pressure wound therapy on wound complications in obese women after caesarean birth: a systematic review and meta-analysis. *Bjog*, 2022. 129(2): p. 196-207.
167. Gillinder, L., et al., Cytokines as a marker of central nervous system autoantibody associated epilepsy. *Epilepsy Res*, 2021. 176: p. 106708.
168. Ginige, S., et al., The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia. *Aust N Z J Obstet Gynaecol*, 2021.
169. Goh, I.Y., et al., Hepatic small vessel neoplasm - A systematic review. *Ann Med Surg (Lond)*, 2021. 72: p. 103004.
170. Golledge, J., et al., Cohort Study Examining the Association of Immunosuppressant Drug Prescription With Major Adverse Cardiovascular and Limb Events in Patients With Peripheral Artery Disease. *Ann Vasc Surg*, 2021.
171. Golledge, J., et al., Cohort Study Examining the Prevalence and Relationship with Outcome of Standard Modifiable Risk Factors in Patients with Peripheral Artery Occlusive and Aneurysmal Disease. *Eur J Vasc Endovasc Surg*, 2021.
172. Golledge, J., et al., Control of modifiable risk factors and major adverse cardiovascular events in people with peripheral artery disease and diabetes. *World J Diabetes*, 2021. 12(6): p. 883-892.
173. Gordon, L.G., et al., Healthcare costs of investigations for stillbirth from a population-based study in Australia. *Aust Health Rev*, 2021. 45(6): p. 735-744.
174. Gould, C., et al., Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target. *Br J Haematol*, 2021. 195(1): p. 113-118.
175. Gould, J.F., et al., Protocol for assessing if behavioural functioning of infants born <29 weeks' gestation is improved by omega-3 long-chain polyunsaturated fatty acids: follow-up of a randomised controlled trial. *BMJ Open*, 2021. 11(5): p. e044740.
176. Grapotte, M., et al., Discovery of widespread transcription initiation at microsatellites predictable by sequence-based deep neural network. *Nature Communications*, 2021. 12(1).
177. Green, K.N. and D.A. Hume, On the utility of CSF1R inhibitors. *Proc Natl Acad Sci U S A*, 2021. 118(4).
178. Groarke, P., et al., Correlation of magnetic resonance and arthroscopy in the diagnosis of shoulder injury. *ANZ Journal of Surgery*, 2021. 91(10): p. 2145-2152.
179. Gu, B., et al., Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. *BMJ Open*, 2021. 11(7): p. e043921.

180. Gunawan, B., et al., Survival following palliative percutaneous nephrostomy tube insertion in patients with malignant ureteric obstruction: Validating a prognostic model. *Progress in Palliative Care*, 2021.
181. Gupta, A., et al., All-Arthroscopic Muscle Slide and Advancement Technique to Repair Massive Retracted Posterosuperior Rotator Cuff Tears. *Arthroscopy Techniques*, 2021. 10(6): p. e1439-e1446.
182. Gustafsson, L., et al., Australian occupational therapy academic workforce: An examination of retention, work-engagement, and role overload issues. *Scand J Occup Ther*, 2021: p. 1-11.
183. Guyatt, S., et al., Using the Consolidated Framework for Implementation Research to design and implement a perinatal education program in a large maternity hospital. *BMC Health Serv Res*, 2021. 21(1): p. 1077.
184. Haifer, C., et al., Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. *Med J Aust*, 2021. 214(3): p. 128-133.
185. Hamilton, A., P. Jayaratne, and M. Zonta, Metastatic Merkel cell carcinoma and malignant melanoma in a single sentinel lymph node. *SAGE Open Med Case Rep*, 2021. 9: p. 2050313x211023685.
186. Hapgood, G., et al., Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance. *Intern Med J*, 2021.
187. Hardy, J. and M.P. Davis, The Management of Nausea and Vomiting Not Related to Anticancer Therapy in Patients with Cancer. *Curr Treat Options Oncol*, 2021. 22(2): p. 17.
188. Hardy, J., et al., Practice review: Evidence-based quality use of corticosteroids in the palliative care of patients with advanced cancer. *Palliat Med*, 2021: p. 269216320986717.
189. Hardy, J.R. and J. Philip, Interests and conflicts when writing, reviewing and editing papers on voluntary assisted dying. *Intern Med J*, 2021. 51(10): p. 1563-1566.
190. Hastie, E., et al., Epstein-Barr Virus DNA in Pericardial Effusion Causing Subacute Cardiac Tamponade. *CASE (Phila)*, 2021. 5(4): p. 235-238.
191. Hayward, K.L., et al., Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. *Pharmaceuticals (Basel)*, 2021. 14(12).
192. Hayward, K.L., et al., Towards collaborative management of nonalcoholic fatty liver disease (TCM-NAFLD): a 'real-world' pathway for fibrosis risk assessment in primary care. *Intern Med J*, 2021.
193. Haywood, A., et al., Corticosteroids for the management of cancer-related fatigue in adults with advanced cancer. *Cochrane Database of Systematic Reviews*, 2020. 2020(11).
194. He, Y., et al., Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. *Mol Pharm*, 2021. 18(9): p. 3464-3474.
195. Henden, A.S., et al., IFN λ Therapy Prevents Severe Gastrointestinal Graft-versus-Host Disease. *Blood*, 2021.
196. Herbert, A. and J. Hardy, Medicinal cannabis use in palliative care. *Aust J Gen Pract*, 2021. 50(6): p. 363-368.
197. Herren, D.B., et al., Arthroplasty in the hand: what works and what doesn't? *Journal of Hand Surgery: European Volume*, 2021.
198. Hickling, A., et al., Systematic Review: Diabetes Family Conflict in Young People With Type 1 Diabetes. *J Pediatr Psychol*, 2021. 46(9): p. 1091-1109.
199. Hickman, I.J., et al., Telehealth-delivered, Cardioprotective Diet and Exercise Program for Liver Transplant Recipients: A Randomized Feasibility Study. *Transplant Direct*, 2021. 7(3): p. e667.
200. Hill, A., et al., A human factors approach to subcutaneous insulin chart design improves user-performance: An experimental study. *Appl Ergon*, 2021. 94: p. 103389.
201. Hines, E.M., et al., Bacterial infection of fasciotomy wounds following decompression for acute compartment syndrome. *Injury*, 2021. 52(10): p. 2914-2919.
202. Ho, K.K.F., et al., Ruptured Left Gastric Artery Aneurysm Associated with Fibromuscular Dysplasia. *Vasc Endovascular Surg*, 2021: p. 15385744211054267.

203. Hong, A.M., J.R. Stretch, and J.F. Thompson, Treatment of primary Merkel cell carcinoma: Radiotherapy can be an effective, less morbid alternative to surgery. *European Journal of Surgical Oncology*, 2021. 47(2): p. 483-485.
204. Hough, J.L., J. Barton, and L.A. Jardine, A quality appraisal using the AGREE II instrument of endotracheal tube suction guidelines in neonatal intensive care units. *Aust Crit Care*, 2021.
205. Hughes, J.A., et al., The documentation of pain intensity and its influences on care in the emergency department. *Int Emerg Nurs*, 2021. 57: p. 101015.
206. Hume, D.A., et al., The Mononuclear Phagocyte System of the Rat. *J Immunol*, 2021. 206(10): p. 2251-2263.
207. Hunt, R.W., et al., Effect of Treatment of Clinical Seizures vs Electrographic Seizures in Full-Term and Near-Term Neonates: A Randomized Clinical Trial. *JAMA Netw Open*, 2021. 4(12): p. e2139604.
208. Ilvemark, J., et al., Defining transabdominal Intestinal Ultrasound treatment response and remission in Inflammatory Bowel Disease: Systematic review and expert consensus statement. *J Crohn'ss Colitis*, 2021.
209. Indarwati, F., J. Munday, and S. Keogh, Nurse knowledge and confidence on peripheral intravenous catheter insertion and maintenance in pediatric patients: A multicentre cross-sectional study. *J Pediatr Nurs*, 2021. 62: p. 10-16.
210. Inder, W.J., et al., Ex vivo glucocorticoid-induced secreted proteome approach for discovery of glucocorticoid-responsive proteins in human serum. *Proteomics Clin Appl*, 2021: p. e2000078.
211. Ioannides, Z.A., et al., Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein–Barr Virus-Specific T Cell Therapy. *Frontiers in Neurology*, 2021. 12.
212. Irvine, K.M., et al., Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. *Sci Rep*, 2021. 11(1): p. 2858.
213. Janda, M., et al., Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. *Gynecol Oncol*, 2021. 161(1): p. 143-151.
214. Janjua, T.I., et al., Clinical translation of silica nanoparticles. *Nat Rev Mater*, 2021: p. 1-3.
215. Janjua, T.I., et al., Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. *Nanoscale*, 2021. 13(40): p. 16909-16922.
216. Janjua, T.I., et al., Frontiers in the treatment of glioblastoma: Past, present and emerging. *Adv Drug Deliv Rev*, 2021.
217. Jansz, N. and G.J. Faulkner, Endogenous retroviruses in the origins and treatment of cancer. *Genome Biol*, 2021. 22(1): p. 147.
218. Jardine, L., et al., Decreasing delivery room intubations: A quality improvement project. *J Paediatr Child Health*, 2021.
219. Jardine, L., et al., Trial of aerosolised surfactant for preterm infants with respiratory distress syndrome. *Arch Dis Child Fetal Neonatal Ed*, 2021.
220. Jayaratnam, S., R. Franklin, and C. de Costa, A scoping review of maternal near miss assessment in Australia, New Zealand, South-East Asia and the South Pacific region: How, what, why and where to? *Aust N Z J Obstet Gynaecol*, 2021.
221. Jayawardena, R., et al., Impact of portion-control plates (PCP) on weight reduction: A systematic review and meta-analysis of intervention studies. *Obes Res Clin Pract*, 2021.
222. Jennings, B., et al., Information needs of women undergoing gynaecological risk reduction surgery: Applying patient-reported findings to improve service delivery. *Aust N Z J Obstet Gynaecol*, 2021.
223. Jensen, M.E., et al., Maternal asthma and gestational diabetes mellitus: Exploration of potential associations. *Obstet Med*, 2021. 14(1): p. 12-18.
224. Jensen, R.C., et al., Adapting fasting plasma glucose threshold for GDM diagnosis according to the population distribution - An approach to the Danish paradox. *Diabetes Res Clin Pract*, 2021. 175: p. 108832.

225. Job, J., et al., Feasibility of an asynchronous general practitioner-to-general physician eConsultant outpatient substitution program: A Queensland pilot study. *Aust J Gen Pract*, 2021. 50(11): p. 857-862.
226. Jobber, C.J.D., et al., Using the theoretical domains framework to inform strategies to support dietitians undertaking body composition assessments in routine clinical care. *BMC Health Serv Res*, 2021. 21(1): p. 518.
227. Johnson, A.L., et al., Bacteraemia, sepsis and antibiotic resistance in Australian patients with cirrhosis: a population-based study. *BMJ Open Gastroenterol*, 2021. 8(1).
228. Johnson, A.L., et al., Predicting Liver-Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests. *Hepatol Commun*, 2021.
229. Johnson, D., et al., Videogame Play and Wellbeing among a First Episode Psychosis Population. *Proceedings of the ACM on Human-Computer Interaction*, 2021. 5(CHIPLAY).
230. Johnson, P., N. Rosendahl, and K.J. Radford, Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities. *Expert Opin Biol Ther*, 2021: p. 1-8.
231. Johnston, H.E., et al., The inter- and intrarater reliability and feasibility of dietetic assessment of sarcopenia and frailty in potential liver transplant recipients: A mixed-methods study. *Clin Transplant*, 2021. 35(2): p. e14185.
232. Jones, A.P.M., et al., Efficacy of dexamethasone in the management of malignant small bowel obstruction in advanced epithelial ovarian cancer. *Support Care Cancer*, 2021.
233. Kaçmaz, E., et al., International survey on opinions and use of minimally invasive surgery in small bowel neuroendocrine neoplasms. *Eur J Surg Oncol*, 2021.
234. Karlsen, E.A., et al., Appendicular ring: an unusual cause of mechanical small bowel obstruction. *ANZ J Surg*, 2021.
235. Karlsen, E.A., et al., Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review. *Cells*, 2021. 10(5).
236. Karlsen, E.A., et al., Missed diagnosis of a foramen of Winslow internal hernia. *ANZ J Surg*, 2021.
237. Karri, S.R., et al., A Case of Burnt-Out Langerhans Cell Histiocytosis Presenting as Postpartum Hypopituitarism. *AACE Clin Case Rep*, 2021. 7(1): p. 47-50.
238. Kaur, S., et al., Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice. *J Hematol Oncol*, 2021. 14(1): p. 3.
239. Keen, C., et al., Antidepressant use and interpersonal violence perpetration: a protocol for a systematic review and meta-analysis. *BMJ Open*, 2021. 11(1): p. e043306.
240. Keen, C., et al., Periods of altered risk for non-fatal drug overdose: a self-controlled case series. *Lancet Public Health*, 2021. 6(4): p. e249-e259.
241. Keen, C., et al., Prevalence of co-occurring mental illness and substance use disorder and association with overdose: a linked data cohort study among residents of British Columbia, Canada. *Addiction*, 2021.
242. Keshvari, S., et al., CSF1R-dependent macrophages control postnatal somatic growth and organ maturation. *PLoS Genet*, 2021. 17(6): p. e1009605.
243. Khalil, H. and K. Kynoch, Implementation of sustainable complex interventions in health care services: the triple C model. *BMC Health Serv Res*, 2021. 21(1): p. 143.
244. Khan, T., et al., The CDCP1 signalling hub: a target for cancer detection and therapeutic intervention. *Cancer Res*, 2021.
245. Kildea, S., et al., Effect of a Birthing on Country service redesign on maternal and neonatal health outcomes for First Nations Australians: a prospective, non-randomised, interventional trial. *Lancet Glob Health*, 2021. 9(5): p. e651-e659.
246. Kim, B.V., et al., Development of a core outcome set for interventions to prevent stillbirth. *Aust N Z J Obstet Gynaecol*, 2021.
247. Kirby, E., et al., Hopeful dying? The meanings and practice of hope in palliative care family meetings. *Soc Sci Med*, 2021. 291: p. 114471.

248. Klionsky, D.J., et al., Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy*, 2021: p. 1-382.
249. Koh, E.S., et al., Implementation of 3D conformal radiotherapy technology at the National Cancer Centre Mongolia: A successful Asia-Pacific collaborative initiative. *J Med Imaging Radiat Oncol*, 2021. 65(4): p. 454-459.
250. Kong, F. and J. Muir, 5-Fluorouracil: Friend or foe? *Aust J Gen Pract*, 2021. 50(8): p. 557-559.
251. Kozica-Olenski, S., et al., Patient-reported experiences of mealtime care and food access in acute and rehabilitation hospital settings: a cross-sectional survey. *J Hum Nutr Diet*, 2021.
252. Krishnan, R., et al., Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study. *BMC Musculoskelet Disord*, 2021. 22(1): p. 271.
253. Kryza, T., et al., Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. *Nat Chem Biol*, 2021. 17(7): p. 776-783.
254. Kubler, J.M., et al., The effects of exercise during pregnancy on placental composition: A systematic review and meta-analysis. *Placenta*, 2022. 117: p. 39-46.
255. Kumar, V., Going, Toll-like receptors in skin inflammation and inflammatory diseases. *Excli j*, 2021. 20: p. 52-79.
256. Kumar, V., Innate Lymphoid Cells and Adaptive Immune Cells Cross-Talk: A Secret Talk Revealed in Immune Homeostasis and Different Inflammatory Conditions. *Int Rev Immunol*, 2021: p. 1-35.
257. Kumar, V., The Trinity of cGAS, TLR9, and ALRs Guardians of the Cellular Galaxy Against Host-Derived Self-DNA. *Front Immunol*, 2020. 11: p. 624597.
258. Kumar, V., Toll-Like Receptors in Adaptive Immunity. *Handb Exp Pharmacol*, 2021.
259. Kynoch, K. and M.A. Ramis, Challenges and complexities of meeting family needs in the intensive care unit. *JBIC Evidence Synthesis*, 2021. 19(7): p. 1497-1498.
260. Kynoch, K., et al., The effectiveness of educational interventions for health care staff to prevent and manage aggressive behaviors in patients admitted to an acute hospital: a systematic review protocol. *JBIC Evid Synth*, 2021.
261. Kynoch, K., et al., The intensive care unit visiting study: A multisite survey of visitors. *Aust Crit Care*, 2021.
262. Kynoch, K., M.A. Ramis, and A. McArdle, Experiences and needs of families with a relative admitted to an adult intensive care unit: A systematic review of qualitative studies. *JBIC Evidence Synthesis*, 2021. 19(7): p. 1499-1554.
263. Laakso, E.L. and M. Ralph, Maintaining Photobiomodulation Research During the COVID-19 Pandemic. *Photobiomodul Photomed Laser Surg*, 2021. 39(9): p. 579-580.
264. Laakso, E.L., et al., Effect of Transcutaneous Radial Artery Photobiomodulation on Continuous Measures of Interstitial Glucose in a Single Subject: A Brief Report. *Photobiomodul Photomed Laser Surg*, 2021. 39(10): p. 637-641.
265. Labrom, F.R., et al., Adolescent idiopathic scoliosis 3D vertebral morphology, progression and nomenclature: a current concepts review. *Eur Spine J*, 2021. 30(7): p. 1823-1834.
266. Lahoud, M.H. and K.J. Radford, Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A. *Hum Vaccin Immunother*, 2021: p. 1-5.
267. Lam, C.N., et al., The effect of oral omega-3 polyunsaturated fatty acid supplementation on muscle maintenance and quality of life in patients with cancer: A systematic review and meta-analysis. *Clin Nutr*, 2021. 40(6): p. 3815-3826.
268. Launay, M., et al., Three-Dimensional Quantification of Glenoid Bone Loss in Anterior Shoulder Instability: The Anatomic Concave Surface Area Method. *Orthopaedic Journal of Sports Medicine*, 2021. 9(6).
269. Lavergne, M., et al., Tissue factor pathway inhibitor 2 is a potent kallikrein-related protease 12 inhibitor. *Biol Chem*, 2021.
270. Law, S.C., et al., Successful treatment of Epstein-Barr virus-associated primary central nervous system lymphoma due to post-transplantation lymphoproliferative disorder, with ibrutinib and third-party Epstein-Barr virus-specific T cells. *Am J Transplant*, 2021.

271. Lawford, H.L.S., et al., Associations between malaria in pregnancy and neonatal neurological outcomes. *Int J Infect Dis*, 2021. 112: p. 144-151.
272. Lawford, H.L.S., et al., Gestational Age-Specific Distribution of the Hammersmith Neonatal Neurological Examination Scores Among Low-Risk Neonates in Ghana. *Early Human Development*, 2021. 152.
273. Lee, Y.Q., et al., Maternal diet influences fetal growth but not fetal kidney volume in an australian indigenous pregnancy cohort. *Nutrients*, 2021. 13(2): p. 1-18.
274. Lee, Y.S., et al., Human CD141(+) dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model. *J Immunother Cancer*, 2021. 9(3).
275. Lee-Tannock, A., et al., Longitudinal assessment of ventricular strain, tricuspid and mitral annular plane systolic excursion (TAPSE and MAPSE) in fetuses from pregnancies complicated by diabetes mellitus. *European Journal of Obstetrics and Gynecology and Reproductive Biology*, 2021. 256: p. 364-371.
276. Lee-Tannock, A., K. Hay, and S. Kumar, Differences in biomarkers of cardiac dysfunction in cord blood between normal pregnancies and pregnancies complicated by maternal diabetes. *Aust N Z J Obstet Gynaecol*, 2021.
277. Lehn, A., et al., Functional neurological disorders: effective teaching for health professionals. *BMJ Neurol Open*, 2020. 2(1): p. e000065.
278. Leisher, S.H., et al., Systematic review: fetal death reporting and risk in Zika-affected pregnancies. *Trop Med Int Health*, 2021. 26(2): p. 133-145.
279. Leung, F.T., et al., Sensorimotor system changes in adolescent rugby players post-concussion: A prospective investigation from the subacute period through to return-to-sport. *Musculoskelet Sci Pract*, 2021. 57: p. 102492.
280. Lévesque, J.P., et al., Macrophages form erythropoietic niches and regulate iron homeostasis to adapt erythropoiesis in response to infections and inflammation. *Exp Hematol*, 2021.
281. Lévesque, J.P., et al., Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches. *Exp Hematol*, 2021. 100: p. 12-31.e1.
282. Lewis, S., et al., The social meanings of choice in living-with advanced breast cancer. *Social Science and Medicine*, 2021. 280.
283. Li, J., et al., Elucidating the Motif for CpG Oligonucleotide Binding to the Dendritic Cell Receptor DEC-205 Leads to Improved Adjuvants for Liver-Resident Memory. *J Immunol*, 2021. 207(7): p. 1836-1847.
284. Liebert, A., et al., Improvements in clinical signs of Parkinson's disease using photobiomodulation: a prospective proof-of-concept study. *BMC Neurol*, 2021. 21(1): p. 256.
285. Liebert, A., et al., Remote Photobiomodulation Treatment for the Clinical Signs of Parkinson's Disease: A Case Series Conducted During COVID-19. *Photobiomodul Photomed Laser Surg*, 2021.
286. Liley, H.G. and J. Zestic, Reaching for improvement in newborn resuscitation. *Resuscitation*, 2021. 167: p. 407-409.
287. Liley, H.G., M.J. Peek, and J. Daly, Non-invasive prenatal testing: clinical utility and ethical concerns about recent advances. *Med J Aust*, 2021. 215(8): p. 384-384.e1.
288. Liley, H.G., S.B. Hooper, and F.L. Nakwa, Worldwide success of CPAP in the delivery room - Still a work in progress. *Resuscitation*, 2021.
289. Lisowski, Z.M., et al., Use of quantitative real-time PCR to determine the local inflammatory response in the intestinal mucosa and muscularis of horses undergoing small intestinal resection. *Equine Vet J*, 2021.
290. Little, J.P., et al., Morphological changes in the respiratory system: an MRI investigation of differences between the supine and left lateral decubitus positions. *Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization*, 2021.
291. Lo, H.P., et al., Cavin4 interacts with Bin1 to promote T-tubule formation and stability in developing skeletal muscle. *J Cell Biol*, 2021. 220(12).
292. Lobo, Y. and L. Wheller, A narrative review of the roles of topical permethrin and oral ivermectin in the management of infantile scabies. *Australas J Dermatol*, 2021.

293. Lobo, Y. and L. Wheller, Vitiligo in a 9-year-old girl with Koolen-de Vries syndrome. *Dermatol Online J*, 2021. 27(4).
294. Lobo, Y., T. Blake, and L. Wheller, Management of multiple trichoepithelioma: A review of pharmacological therapies. *Australas J Dermatol*, 2021.
295. Lodge, J., C. Flatley, and S. Kumar, The fetal cerebroplacental ratio in pregnancies complicated by hypertensive disorders of pregnancy. *Aust N Z J Obstet Gynaecol*, 2021.
296. Loermans, S., J. Walsh, and R. Shulman, Case report: Acute calcific tendonitis of flexor hallucis brevis. *ANZ J Surg*, 2021.
297. Lovell, S., et al., A Suite of Activity-Based Probes To Dissect the KLK Activome in Drug-Resistant Prostate Cancer. *J Am Chem Soc*, 2021. 143(23): p. 8911-8924.
298. Lowe, S.A., et al., Update on pulmonary embolism in pregnancy and post-partum: The Society of Obstetric Medicine of Australia and New Zealand Position Statement on Pulmonary Embolism in Pregnancy and Post-partum. *Aust N Z J Obstet Gynaecol*, 2021.
299. Lucas, I.M., et al., Gestational diabetes is associated with postpartum hemorrhage in Indigenous Australian women in the PANDORA study: A prospective cohort. *Int J Gynaecol Obstet*, 2021. 155(2): p. 296-304.
300. Luciano, M., et al., The influence of X chromosome variants on trait neuroticism. *Mol Psychiatry*, 2021. 26(2): p. 483-491.
301. Ludwig, K., et al., Type 2 diabetes in children and adolescents across Australia and New Zealand: A 6-year audit from The Australasian Diabetes Data Network (ADDN). *Pediatric Diabetes*, 2021. 22(3): p. 380-387.
302. Lukowski, S.W., et al., Absence of Batf3 reveals a new dimension of cell state heterogeneity within conventional dendritic cells. *iScience*, 2021. 24(5): p. 102402.
303. Lumchee, M., et al., Therapeutic plasma exchange for Graves' disease in pregnancy. *Obstetric Medicine*, 2021.
304. Macías, F., et al., TBP and SNAP50 transcription factors bind specifically to the Pr77 promoter sequence from trypanosomatid non-LTR retrotransposons. *Parasit Vectors*, 2021. 14(1): p. 313.
305. MacKay, D., et al., Improving systems of prenatal and postpartum care for hyperglycemia in pregnancy: A process evaluation. *Int J Gynaecol Obstet*, 2021. 155(2): p. 179-194.
306. Madrid, L.I., et al., Cholinergic regulation of adult hippocampal neurogenesis and hippocampus-dependent functions. *Int J Biochem Cell Biol*, 2021. 134: p. 105969.
307. Madsen, L.R., et al., Do variations in insulin sensitivity and insulin secretion in pregnancy predict differences in obstetric and neonatal outcomes? *Diabetologia*, 2021. 64(2): p. 304-312.
308. Mah, B.L., et al., Psychological Distress, Stressful Life Events and Social Disadvantage in Pregnant Indigenous Australian Women Residing in Rural and Remote NSW: a Longitudinal Cohort Study. *J Racial Ethn Health Disparities*, 2021.
309. Mahmoud, A., et al., Lateral Extra-articular Tenodesis Combined With Anterior Cruciate Ligament Reconstruction Is Effective in Knees With Additional Features of Lateral, Hyperextension, or Increased Rotational Laxity: A Matched Cohort Study. *Arthroscopy - Journal of Arthroscopic and Related Surgery*, 2021.
310. Malihi, Z., et al., Modifiable Early Childhood Risk Factors for Obesity at Age Four Years. *Child Obes*, 2021.
311. Maltby, S., et al., Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. *Intern Med J*, 2021. 51(2): p. 169-180.
312. Manchery, N., et al., Cognitive function and oral health in relapsing-remitting multiple sclerosis. *Clin Oral Investig*, 2021.
313. Mantha, S., L.G. Coulthard, and R. Campbell, CSF-space volumetric change following posterior fossa decompression in paediatric Chiari type-I malformation: a correlation with outcome. *Childs Nerv Syst*, 2021.

314. Mar, E., K. Taylor, and P. Mollee, Response of factor X deficiency to daratumumab in the treatment of AL amyloidosis: a novel finding. *BMJ Case Rep*, 2021. 14(4).
315. Martin, E., et al., Adherence to best practice: Preventing surgical site infection following caesarean section in Australia. *Aust N Z J Obstet Gynaecol*, 2021.
316. Marynowski-Traczyk, D., et al., Optimising emergency department and acute care for people experiencing mental health problems: A nominal group study. *Australian Health Review*, 2021.
317. Mazzone, D. and J. Muir, A Comment on: "Patient and Tumour Characteristics of Keratoacanthoma in a Large, Community-based Cohort Study from Queensland, Australia". *Acta Derm Venereol*, 2021. 101(10): p. adv00578.
318. Mazzone, D. and J. Muir, A guide to curettage and cautery in the management of skin lesions. *Aust J Gen Pract*, 2021. 50(12): p. 893-897.
319. Mazzone, D. and J. Muir, A persistent progressive patch on the face. *Aust J Gen Pract*, 2021. 50(7): p. 491-493.
320. Mazzone, D. and J. Muir, Assessment and management of a longstanding penile lesion. *Aust J Gen Pract*, 2021. 50(8): p. 564-566.
321. Mazzone, D. and J. Muir, Considerations in the management of keratoacanthoma. *Br J Dermatol*, 2021.
322. Mazzone, D. and J. Muir, Dealing with lentigo maligna: A challenging case. *Aust J Gen Pract*, 2021. 50(4): p. 222-224.
323. Mazzone, D. and J. Muir, Response to "Interventions for basal cell carcinoma: abridged Cochrane systematic reviews and GRADE assessments". *Br J Dermatol*, 2021.
324. Mazzone, D., et al., A reply to 'The impact of incomplete clinical information and initial biopsy technique on the histopathologic diagnosis of cutaneous melanoma'. *Australas J Dermatol*, 2021.
325. Mazzone, D., et al., Genital premalignant and malignant diseases: a retrospective study of male genital skin biopsies. *Int J Dermatol*, 2021.
326. Mazzone, D., P. Kubler, and J. Muir, Recognising skin manifestations of rheumatological disease. *Aust J Gen Pract*, 2021. 50(12): p. 873-878.
327. McAvoy, S., A. Staib, and G. Treston, Can a system dynamics model of the emergency department show which levers reduce bottlenecks and delays to improve access to care? *Systems Research and Behavioral Science*, 2021. 38(1): p. 61-79.
328. McCarthy, J.S., et al., Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage plasmodium falciparum. *Antimicrobial Agents and Chemotherapy*, 2021. 65(2).
329. McIntyre, H.D., et al., Update on diagnosis of hyperglycemia in pregnancy and gestational diabetes mellitus from FIGO's Pregnancy & Non-Communicable Diseases Committee. *Int J Gynaecol Obstet*, 2021. 154(2): p. 189-194.
330. McLeod, G., et al., Variation in Neonatal Nutrition Practice and Implications: A Survey of Australia and New Zealand Neonatal Units. *Front Nutr*, 2021. 8: p. 642474.
331. McPhail, S.M., et al., Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis. *JGH Open*, 2021. 5(1): p. 133-142.
332. Meakin, A.S., et al., Identification of placental androgen receptor isoforms in a sheep model of maternal allergic asthma. *Placenta*, 2021. 104: p. 232-235.
333. Meakin, A.S., et al., Let's talk about placental sex, baby: Understanding mechanisms that drive female- and male-specific fetal growth and developmental outcomes. *International Journal of Molecular Sciences*, 2021. 22(12).
334. Medeiros, P., et al., Effectiveness of neonatal "near miss" audits in reducing perinatal morbidity and mortality: a systematic review protocol. *JBI Evid Synth*, 2021.
335. Melamed, N., et al., FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal growth restriction. *Int J Gynaecol Obstet*, 2021. 152 Suppl 1: p. 3-57.

336. Melo, H.M., et al., Ictal fear is associated with anxiety symptoms and interictal dysphoric disorder in drug-resistant mesial temporal lobe epilepsy. *Epilepsy Behav*, 2021. 115: p. 107548.
337. Meloncelli, N., S.A. Wilkinson, and S. de Jersey, Searching for Utopia, the Challenge of Standardized Medical Nutrition Therapy Prescription in Gestational Diabetes Mellitus Management: A Critical Review. *Semin Reprod Med*, 2021.
338. Mengistu, T.S., et al., Factors Associated with Increased Risk of Early Severe Neonatal Morbidity in Late Preterm and Early Term Infants. *J Clin Med*, 2021. 10(6).
339. Merollini, K.M.D. and M. Beckmann, Induction of labor using balloon catheter as an outpatient versus prostaglandin as an inpatient: A cost-effectiveness analysis. *Eur J Obstet Gynecol Reprod Biol*, 2021. 260: p. 124-130.
340. Millard, S.M., et al., Fragmentation of tissue-resident macrophages during isolation confounds analysis of single-cell preparations from mouse hematopoietic tissues. *Cell Rep*, 2021. 37(8): p. 110058.
341. Min, S., et al., Absence of coding somatic single nucleotide variants within well-known candidate genes in late-onset sporadic Alzheimer's Disease based on the analysis of multi-omics data. *Neurobiol Aging*, 2021.
342. Mohamed, A.Z., et al., Traumatic brain injury fast-forwards Alzheimer's pathology: evidence from amyloid positron emission tomography imaging. *J Neurol*, 2021.
343. Mohammadi, S., et al., Adoptive transfer of Tregs: A novel strategy for cell-based immunotherapy in spontaneous abortion: Lessons from experimental models. *International Immunopharmacology*, 2021. 90.
344. Monterosso, M.E., et al., Using the Microwell-mesh to culture microtissues in vitro and as a carrier to implant microtissues in vivo into mice. *Sci Rep*, 2021. 11(1): p. 5118.
345. Moraa, I., et al., Heliox for croup in children. *Cochrane Database Syst Rev*, 2021. 8(8): p. Cd006822.
346. Morris, A.R., et al., Mental health, neurodevelopmental, and family psychosocial profiles of children born very preterm at risk of an early-onset anxiety disorder. *Dev Med Child Neurol*, 2021.
347. Morton, A. and S. Kumar, Alagille syndrome and pregnancy. *Obstet Med*, 2021. 14(1): p. 39-41.
348. Morton, A. and S. Teasdale, Physiological changes in pregnancy and their influence on the endocrine investigation. *Clin Endocrinol (Oxf)*, 2022. 96(1): p. 3-11.
349. Morton, A., Absent erythropoietin response to anaemia with mild to moderate chronic kidney disease in pregnancy. *Nephrology (Carlton)*, 2021. 26(2): p. 205.
350. Morton, A., Blue eyes, brittle bones. *Aust J Gen Pract*, 2021. 50(6): p. 377-378.
351. Morton, A., et al., Anaemia in chronic kidney disease pregnancy. *Obstet Med*, 2021. 14(2): p. 116-120.
352. Morton, A., et al., Pregnancy outcomes in women with hyponatraemia and preeclampsia: Case series and literature review. *Pregnancy Hypertens*, 2021. 26: p. 38-41.
353. Morton, A., Hyperventilation imitating preeclampsia. *Obstetric Medicine*, 2021.
354. Morton, A., Hypoglycaemia in non-diabetic pregnancy. *Obstetric Medicine*, 2021.
355. Morton, A., Letter to the Editor: Thiamine deficiency and bariatric surgery. *Obstetric Medicine*, 2021.
356. Morton, A., Low haptoglobin and a positive direct antiglobulin test without haemolysis in pregnancy. *Obstetric Medicine*, 2021.
357. Morton, A., Physiological Changes and Cardiovascular Investigations in Pregnancy. *Heart Lung and Circulation*, 2021. 30(1): p. e6-e15.
358. Morton, A., Postpartum collapse. *Obstet Med*, 2021. 14(1): p. 46-49.
359. Morton, A., Pregnancy complicated by neurological and neurosurgical conditions – The evidence regarding mode of delivery. *Obstetric Medicine*, 2021.
360. Morton, A., Review article: Diagnosing acute pancreatitis in diabetes mellitus. *Emerg Med Australas*, 2021.
361. Morton, S. and J. Muir, Field cancerization in the skin: Past errors repeated. *J Am Acad Dermatol*, 2021.
362. Morton, S., J. Muir, and D. Kennedy, A longstanding pigmented lesion. *Aust J Gen Pract*, 2021. 50(8): p. 550-552.
363. Moses, G., The safety of commonly used vitamins and minerals. *Aust Prescr*, 2021. 44(4): p. 119-123.

364. Muir, J. and J. Perron, The use of a glove tourniquet in digital surgery results in an unnecessary risk to the patient - a letter to the editor. *Australas J Dermatol*, 2021.
365. Muirhead, R., et al., Safety and effectiveness of parent- or nurse-controlled analgesia in neonates: a systematic review. *JBI Evid Synth*, 2021.
366. Mullins, T.P., et al., Maternal gut microbiota displays minor changes in overweight and obese women with GDM. *Nutr Metab Cardiovasc Dis*, 2021. 31(7): p. 2131-2139.
367. Murphy, M.T. and J. Radovanovic, Patient satisfaction with physiotherapists is not inferior to surgeons in an arthroplasty review clinic: non-inferiority study of an expanded scope model of care. *Aust Health Rev*, 2021. 45(1): p. 104-109.
368. Nair, S., et al., Extracellular vesicle-associated miRNAs are an adaptive response to gestational diabetes mellitus. *J Transl Med*, 2021. 19(1): p. 360.
369. Nair, S., et al., Extracellular vesicles and their potential role inducing changes in maternal insulin sensitivity during gestational diabetes mellitus. *Am J Reprod Immunol*, 2021. 85(2): p. e13361.
370. Najman, J.M., et al., Does the millennial generation of women experience more mental illness than their mothers? *BMC Psychiatry*, 2021. 21(1): p. 359.
371. Nalkurthi, C., et al., ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis. *JHEP Rep*, 2022. 4(1): p. 100386.
372. Nastasi, D.R., et al., The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm. *Eur J Vasc Endovasc Surg*, 2021. 62(4): p. 643-650.
373. Natari, R.B., et al., Long term impact of the WHI studies on information-seeking and decision-making in menopause symptoms management: a longitudinal analysis of questions to a medicines call centre. *BMC Women's Health*, 2021. 21(1): p. 348.
374. Nath, K. and M.K. Gandhi, Targeted Treatment of Follicular Lymphoma. *J Pers Med*, 2021. 11(2).
375. Nath, K., et al., A retrospective analysis of the investigative practices of acute limb ischaemia presenting with an unknown aetiology. *ANZ J Surg*, 2021.
376. Nath, K., et al., Hepatitis B in haematology patients receiving intravenous immunoglobulin: highlighting a core issue. *Intern Med J*, 2021. 51(11): p. 1981-1982.
377. Nath, K., et al., Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. *Blood Adv*, 2021. 5(12): p. 2644-2649.
378. Navaratnam, D., et al., Implicit motor imagery using laterality recognition in functional movement disorders. *J Clin Neurosci*, 2021. 89: p. 139-143.
379. Nawaz, A., et al., The importance of glycogen molecular structure for blood glucose control. *iScience*, 2021. 24(1).
380. Ndayishimiye, J., et al., Engineering mesoporous silica nanoparticles towards oral delivery of vancomycin. *J Mater Chem B*, 2021. 9(35): p. 7145-7166.
381. Ndayishimiye, J., et al., Supercritical carbon dioxide assisted complexation of benzimidazole: γ -cyclodextrin for improved dissolution. *Int J Pharm*, 2021. 596: p. 120240.
382. Neaves, B., J.J. Bell, and S. McCray, Impact of room service on nutritional intake, plate and production waste, meal quality and patient satisfaction and meal costs: A single site pre-post evaluation. *Nutr Diet*, 2021.
383. Ngo, M.D., S. Bartlett, and K. Ronacher, Diabetes-associated susceptibility to tuberculosis: Contribution of hyperglycemia vs. dyslipidemia. *Microorganisms*, 2021. 9(11).
384. Ngoo, A. and J. Hirst, Ureteric calculus with migration into psoas muscle - Case report and literature review. *Urol Case Rep*, 2021. 35: p. 101552.
385. Nickson, C.P., et al., Translational simulation: from description to action. *Adv Simul (Lond)*, 2021. 6(1): p. 6.
386. Nogueira, R.G., et al., Global Impact of COVID-19 on Stroke Care and Intravenous Thrombolysis. *Neurology*, 2021.

387. Nowlan, B., et al., Human bone marrow-derived stromal cell behavior when injected directly into the bone marrow of NOD-scid-gamma mice pre-conditioned with sub-lethal irradiation. *Stem Cell Res Ther*, 2021. 12(1): p. 231.
388. Nyanchoga, M.M., P. Lee, and G. Barbery, Exploring electronic health records to estimate the extent of catch-up immunisation and factors associated with under-immunisation among refugees and asylum seekers in south east Queensland. *Vaccine*, 2021. 39(42): p. 6238-6244.
389. Odia, T., et al., The Peripheral Blood Transcriptome Is Correlated With PET Measures of Lung Inflammation During Successful Tuberculosis Treatment. *Front Immunol*, 2020. 11: p. 596173.
390. Oliphant, J., et al., The wellbeing and health needs of a cohort of transgender young people accessing specialist medical gender-affirming healthcare in Auckland. *N Z Med J*, 2021. 134(1541): p. 33-44.
391. Onifade, O., et al., Effectiveness of interventions to optimise dietary intakes in the first 1000 d of life in Indigenous children: a systematic review. *Public Health Nutr*, 2021: p. 1-14.
392. Onifade, O.M., et al., Dietary intake of Indigenous Australian infants and young children in the Gomeri gaaynggal cohort. *Nutr Diet*, 2021.
393. Opperman, M., et al., Chronological Metabolic Response to Intensive Phase TB Therapy in Patients with Cured and Failed Treatment Outcomes. *ACS Infect Dis*, 2021. 7(6): p. 1859-1869.
394. Ovadia, C., et al., Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual participant data meta-analysis. *Lancet Gastroenterol Hepatol*, 2021. 6(7): p. 547-558.
395. Page, D., et al., Pasteurised donor human milk audit: What is happening in the neonatal critical care unit? *J Paediatr Child Health*, 2021.
396. Palmer, S.C., et al., Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: Systematic review and network meta-analysis of randomised controlled trials. *The BMJ*, 2021. 372.
397. Papaluca, T., et al., Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics. *Clinical Infectious Diseases*, 2021. 73(9): p. E3288-E3295.
398. Paquin, V., et al., Positive cognitive appraisal "buffers" the long-term effect of peritraumatic distress on maternal anxiety: The Queensland Flood Study. *Journal of Affective Disorders*, 2021. 278: p. 5-12.
399. Parekh, K., et al., Tacrolimus encapsulated mesoporous silica nanoparticles embedded hydrogel for the treatment of atopic dermatitis. *Int J Pharm*, 2021. 608: p. 121079.
400. Parkinson, B., et al., Intraosseous Regional Prophylactic Antibiotics Decrease the Risk of Prosthetic Joint Infection in Primary TKA: A Multicenter Study. *Clin Orthop Relat Res*, 2021. 479(11): p. 2504-2512.
401. Pather, K., S. Dilgir, and A. Rane, The ThermiVa In Genital Hiatus Treatment (TIGHT) Study. *Sex Med*, 2021. 9(6): p. 100427.
402. Pather, P., et al., Incontinence-associated dermatitis: who is affected? *J Wound Care*, 2021. 30(4): p. 261-267.
403. Patkar, O.L., et al., A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. *Sci Rep*, 2021. 11(1): p. 11252.
404. Patkar, O.L., et al., Analysis of homozygous and heterozygous Csf1r knockout in the rat as a model for understanding microglial function in brain development and the impacts of human CSF1R mutations. *Neurobiol Dis*, 2021. 151: p. 105268.
405. Paxton-Hall, T., et al., Spontaneous coronary artery dissection in the third trimester-Implications for investigation and delivery. *Clin Case Rep*, 2021. 9(8): p. e04675.
406. Pearce, L.A., et al., A rapid review of early guidance to prevent and control COVID-19 in custodial settings. *Health Justice*, 2021. 9(1): p. 27.
407. Perera, M., et al., Advancing Traditional Prostate-specific Antigen Kinetics in the Detection of Prostate Cancer: A Machine Learning Model. *Eur Urol Focus*, 2021.
408. Petit, C., et al., Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. *Lancet Oncol*, 2021. 22(5): p. 727-736.

409. Pires-Menard, A., C. Flatley, and S. Kumar, Severe neonatal outcomes associated with emergency cesarean section at term. *J Matern Fetal Neonatal Med*, 2021. 34(4): p. 629-633.
410. Pitney, D.T. and D.J. Muir, Single centre, single operator retrospective analysis of base transection rates in shave procedures for melanoma diagnosis. *J Am Acad Dermatol*, 2020.
411. Pitney, T. and J. Muir, Comment on "Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma: One-year results of a noninferiority, randomized, controlled trial". *Journal of the American Academy of Dermatology*, 2021. 84(1): p. e55.
412. Pitney, T. and J. Muir, The use of shave excision by dermatologists in Australia: A consensus survey. *Australas J Dermatol*, 2021.
413. Pitney, T., E. Shao, and J. Muir, A Reply to 'Think before you shave: factors influencing choice of biopsy technique for invasive melanoma and effect on definitive management'. *Australas J Dermatol*, 2021. 62(1): p. 96-97.
414. Poon, L.C., et al., A literature review and best practice advice for second and third trimester risk stratification, monitoring, and management of pre-eclampsia: Compiled by the Pregnancy and Non-Communicable Diseases Committee of FIGO (the International Federation of Gynecology and Obstetrics). *Int J Gynaecol Obstet*, 2021. 154 Suppl 1: p. 3-31.
415. Poth, A.G., et al., Effects of backbone cyclization on the pharmacokinetics and drug efficiency of the orally active analgesic conotoxin cVc1.1. *Medicine in Drug Discovery*, 2021. 10.
416. Prakash, A., J. Muir, and D. Kennedy, Recurrent intraepidermal carcinoma of the scalp: A common skin malignancy presenting important management considerations on a high-risk site. *Aust J Gen Pract*, 2021. 50(8): p. 570-572.
417. Pramanick, A., et al., A reasoned approach towards administering COVID-19 vaccines to pregnant women. *Prenat Diagn*, 2021. 41(8): p. 1018-1035.
418. Prasad, M.A. and M.K. Chakravarthy, Review of complex regional pain syndrome and the role of the neuroimmune axis. *Molecular Pain*, 2021. 17.
419. Prentice, R.E., et al., SARS-CoV-2 vaccination in patients with inflammatory bowel disease. *GastroHep*, 2021. 3(4): p. 212-228.
420. Pridans, C., et al., Transcriptomic Analysis of Rat Macrophages. *Front Immunol*, 2020. 11: p. 594594.
421. Prieto Ramos, J., et al., Clinical and Echocardiographic Findings in an Aged Population of Cavalier King Charles Spaniels. *Animals* 2021. 11(4).
422. Prieto Ramos, J., et al., Clinical and Echocardiographic Findings in an Aged Population of Cavalier King Charles Spaniels. *Animals (Basel)*, 2021. 11(4).
423. Proctor, M., et al., Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. *Cancers (Basel)*, 2021. 13(15).
424. Psifidi, A., et al., Quantitative trait loci and transcriptome signatures associated with avian heritable resistance to *Campylobacter*. *Sci Rep*, 2021. 11(1): p. 1623.
425. Pujara, N., et al., Oral Delivery of β -Lactoglobulin-Nanosphere-Encapsulated Resveratrol Alleviates Inflammation in Winnie Mice with Spontaneous Ulcerative Colitis. *Mol Pharm*, 2021. 18(2): p. 627-640.
426. Pujara, N., et al., pH - Responsive colloidal carriers assembled from β -lactoglobulin and Epsilon poly-L-lysine for oral drug delivery. *J Colloid Interface Sci*, 2020. 589: p. 45-55.
427. Pumpa, K.L., et al., Identifying women at risk of weight gain after a breast cancer diagnosis: Results from a cohort of Australian women. *Health Promot J Austr*, 2021.
428. Pyke, C., A. Anthony, and J. Archer, Surgical Education: the RACS Model. *Indian Journal of Surgery*, 2021.
429. Rad, H.S., et al., The Effects of COVID-19 on the Placenta During Pregnancy. *Front Immunol*, 2021. 12: p. 743022.
430. Ramanayake, N., et al., NKX3.1 immunohistochemistry is highly specific for the diagnosis of mesenchymal chondrosarcomas: experience in the Australian population. *Pathology*, 2021.
431. Ramarao-Milne, P., et al., Histone Modifying Enzymes in Gynaecological Cancers. *Cancers (Basel)*, 2021. 13(4).

432. Rao, V. and G. Hariharan, Early-onset SARS-CoV-2 infection in neonates born to COVID positive mothers. *Acta Paediatr*, 2021. 110(8): p. 2480-2481.
433. Rasmussen, J., et al., An early proinflammatory transcriptional response to tau pathology is age-specific and foreshadows reduced tau burden. *Brain Pathol*, 2021: p. e13018.
434. Raza, A., et al., Liquid CO₂ Formulated Mesoporous Silica Nanoparticles for pH-Responsive Oral Delivery of Meropenem. *ACS Biomater Sci Eng*, 2021.
435. Raza, A., et al., Microfluidic assembly of pomegranate-like hierarchical microspheres for efflux regulation in oral drug delivery. *Acta Biomater*, 2021. 126: p. 277-290.
436. Raza, A., et al., PLGA encapsulated γ -cyclodextrin-meropenem inclusion complex formulation for oral delivery. *Int J Pharm*, 2021. 597: p. 120280.
437. Rigauts, C., et al., *Rothia mucilaginosa* is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. *Eur Respir J*, 2021.
438. Roberts, K., et al., Letter to the editor: re Lu et al. *Supportive Care in Cancer*, 2021. 29(1).
439. Roberts, S., P. Collins, and M. Rattray, Identifying and Managing Malnutrition, Frailty and Sarcopenia in the Community: A Narrative Review. *Nutrients*, 2021. 13(7).
440. Robertson, C.A., et al., Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network. *Diabetes Obes Metab*, 2022. 24(2): p. 354-361.
441. Robertson, C.A., et al., Longitudinal audit of assessment and pharmaceutical intervention for cardiovascular risk in the Australasian Diabetes Data Network. *Diabetes, Obesity and Metabolism*, 2021.
442. Robledo, K.P., et al., Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial. *Lancet Child Adolesc Health*, 2021.
443. Roff, A.J., et al., Maternal asthma during pregnancy and risks of allergy and asthma in progeny: a systematic review protocol. *JBI Evid Synth*, 2021.
444. Rohit, A., et al., Screening rates for diabetic retinopathy among Aboriginal and Torres Strait Islander women with hyperglycaemia in pregnancy: The PANDORA cohort study. *Clin Exp Ophthalmol*, 2021. 49(7): p. 765-767.
445. Roland, D., et al., Gender equity in free open access medical education. *Clin Teach*, 2021. 18(5): p. 571.
446. Roney, M.S.I., et al., IgM and IgA augmented autoantibody signatures improve early-stage detection of colorectal cancer prior to nodal and distant spread. *Clin Transl Immunology*, 2021. 10(9): p. e1330.
447. Ruscica, M., et al., Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). *Prog Cardiovasc Dis*, 2021.
448. Sadras, F., et al., Altered Calcium Influx Pathways in Cancer-Associated Fibroblasts. *Biomedicines*, 2021. 9(6).
449. Sadras, F., G.R. Monteith, and S.J. Roberts-Thomson, An Emerging Role for Calcium Signaling in Cancer-Associated Fibroblasts. *Int J Mol Sci*, 2021. 22(21).
450. Sahin, K.B., et al., Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer. *Cancers (Basel)*, 2021. 13(18).
451. Saif, Z., A.S. Meakin, and V.L. Clifton, A preferential switch between placental GR exon 1 promoter variants in the presence of maternal asthma or inflammation upregulates GR α D isoforms. *Placenta*, 2021. 108: p. 64-72.
452. Sanaei, R., et al., Protease-activated receptor-2 promotes osteogenesis in skeletal mesenchymal stem cells at the expense of adipogenesis: Involvement of interleukin-6. *Bone Rep*, 2021. 15: p. 101113.
453. Sandham, V., A.E. Hill, and F. Hinchliffe, The current practices of Australian speech-language pathologists in providing communication services to children with autism spectrum disorder. *Int J Speech Lang Pathol*, 2021: p. 1-11.

454. Schoenaker, D., et al., Prevention of Gestational Diabetes: The Role of Dietary Intake, Physical Activity, and Weight before, during, and between Pregnancies. *Semin Reprod Med*, 2021.
455. Schulze, M.G. and M.G. Young, Tracheal Dilatation of an Idiopathic Subglottic Stenosis in a Near-Term Parturient at 36 Weeks of Gestation Using Spontaneous Respiration Using Intravenous Anesthesia and Hi-Flow Nasal Oxygen: A Case Report. *A A Pract*, 2021. 15(4): p. e01450.
456. Schweitzer, D.R., J. Ting, and B. von Hippel, Diagnostic reasoning is associated with lower physician satisfaction with patient communication. *Intern Med J*, 2021.
457. Scott, N.P., et al., Characterising (18)F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging. *Br J Cancer*, 2021.
458. Sehgal, A., K.M. Irvine, and D.A. Hume, Functions of macrophage colony-stimulating factor (CSF1) in development, homeostasis, and tissue repair. *Semin Immunol*, 2021. 54: p. 101509.
459. Sengal, A.T., et al., Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progesterin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer. *Cancers (Basel)*, 2021. 13(7).
460. Sexton, J., D. Ellwood, and V. Flenady, Challenges in developing prediction models for stillbirth. *BJOG: An International Journal of Obstetrics and Gynaecology*, 2021. 128(2): p. 251.
461. Sexton, J., et al., Systematic review of ambient temperature exposure during pregnancy and stillbirth: Methods and evidence. *Environ Res*, 2021. 197: p. 111037.
462. Sexton, J.K., et al., Prospective cohort study: Causes of stillbirth in Australia 2013-2018. *Aust N Z J Obstet Gynaecol*, 2021.
463. Shanavas, M., et al., Intratumoral T-cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B-cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R-CHOP) chemoimmunotherapy. *Clin Transl Immunology*, 2021. 10(11): p. e1351.
464. Sharma, S., et al., Extracellular Vesicle Nanoarchitectonics for Novel Drug Delivery Applications. *Small*, 2021. 17(42): p. e2102220.
465. Shaw, C. and S. Couzos, Integration of non-dispensing pharmacists into primary healthcare services: An umbrella review and narrative synthesis of the effect on patient outcomes. *Aust J Gen Pract*, 2021. 50(6): p. 403-408.
466. Sheng, Y.H., et al., A Nucleotide Analog Prevents Colitis-Associated Cancer via Beta-Catenin Independently of Inflammation and Autophagy. *Cellular and Molecular Gastroenterology and Hepatology*, 2021. 11(1): p. 33-53.
467. Sher, M., et al., Rare case of Morgagni hernia presenting with cyanotic spells in a neonate. *J Paediatr Child Health*, 2021. 57(2): p. 289-292.
468. Sherr, J.L., et al., Hemoglobin A1c Patterns of Youth With Type 1 Diabetes 10 Years Post Diagnosis From 3 Continents. *Pediatrics*, 2021. 148(2).
469. Sherrell, H.C., et al., Women's and clinician's acceptability of participation in a hypothetical obstetric randomized controlled trial: a qualitative survey. *J Matern Fetal Neonatal Med*, 2021: p. 1-7.
470. Shi, C., et al., Comprehensive Landscape of Heparin Therapy for COVID-19. *Carbohydr Polym*, 2021. 254: p. 117232.
471. Singh, T.P., et al., Association of chronic venous disease with major adverse cardiovascular events. *J Vasc Surg Venous Lymphat Disord*, 2021.
472. Sinha, R., et al., Pre-Diabetes Increases Tuberculosis Disease Severity, While High Body Fat Without Impaired Glucose Tolerance Is Protective. *Front Cell Infect Microbiol*, 2021. 11: p. 691823.
473. Sjoquist, K.M., et al., REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer. *Gynecol Oncol*, 2021.
474. Smith, B., et al., The use of transthoracic echocardiography in caesarean section surgical patients in the intensive care unit: A retrospective cohort study. *Aust N Z J Obstet Gynaecol*, 2021.

475. Smith, J., J. Muir, and D. Kennedy, To cryo or not to cryo? A persistent scalp lesion. *Aust J Gen Pract*, 2021. 50(11): p. 840-843.
476. Smith, N.A., et al., A prospective study of risk factors for hamstring injury in Australian football league players. *J Sports Sci*, 2021: p. 1-7.
477. Smith, N.A., et al., Lower limb joint position sense and prospective hamstring injury. *Musculoskelet Sci Pract*, 2021. 53: p. 102371.
478. Smits, N., et al., No evidence of human genome integration of SARS-CoV-2 found by long-read DNA sequencing. *Cell Rep*, 2021. 36(7): p. 109530.
479. Snelson, M., et al., Long Term High Protein Diet Feeding Alters the Microbiome and Increases Intestinal Permeability, Systemic Inflammation and Kidney Injury in Mice. *Mol Nutr Food Res*, 2021: p. e2000851.
480. Snelson, M., et al., Processed foods drive intestinal barrier permeability and microvascular diseases. *Sci Adv*, 2021. 7(14).
481. So, W.K.W., et al., Symptom clusters experienced by breast cancer patients at various treatment stages: A systematic review. *Cancer Med*, 2021. 10(8): p. 2531-2565.
482. Somerville, M., et al., How do healthcare providers support people with prediabetes to eat well? An in-depth, mixed-methods case study of provider practices. *Aust J Gen Pract*, 2021. 50(7): p. 497-504.
483. Steane, S.E., et al., Maternal choline supplementation in a rat model of periconceptional alcohol exposure: Impacts on the fetus and placenta. *Alcohol Clin Exp Res*, 2021.
484. Steane, S.E., et al., Prenatal alcohol consumption and placental outcomes: a systematic review and meta-analysis of clinical studies. *Am J Obstet Gynecol*, 2021.
485. Steriade, C., et al., Discerning the Role of Autoimmunity and Autoantibodies in Epilepsy: A Review. *JAMA Neurol*, 2021. 78(11): p. 1383-1390.
486. Stewart, A.C., et al., Psychiatric well-being among men leaving prison reporting a history of injecting drug use: A longitudinal analysis. *Aust N Z J Psychiatry*, 2021: p. 48674211048143.
487. Stewart, A.C., et al., Strategies to maximise study retention and limit attrition bias in a prospective cohort study of men reporting a history of injecting drug use released from prison: the prison and transition health study. *BMC Med Res Methodol*, 2021. 21(1): p. 185.
488. Stewart, A.C., et al., The Prison and Transition Health (PATH) cohort study: Prevalence of health, social, and crime characteristics after release from prison for men reporting a history of injecting drug use in Victoria, Australia. *Drug Alcohol Depend*, 2021. 227: p. 108970.
489. Stewart, T.A., et al., Mammary mechanobiology - investigating roles for mechanically activated ion channels in lactation and involution. *Journal of cell science*, 2021. 134(1).
490. Sturgess, D.J., et al., Left Ventricular Impaired Relaxation and Interstitial Myocarditis Identified in Sepsis-Associated Cardiac Dysfunction: Use of a Rodent Model. *Med Sci Monit*, 2021. 27: p. e929512.
491. Sudhindar, P.D., et al., Hcv activates somatic I1 retrotransposition—a potential hepatocarcinogenesis pathway. *Cancers*, 2021. 13(20).
492. Sun, C. and J. Muir, A solitary penile lesion. *Aust J Gen Pract*, 2021. 50(12): p. 911-913.
493. Sun, E.J., et al., Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. *Biomedicines*, 2021. 9(11).
494. Swarnamali, H., et al., Coconut oil consumption and bodyweight reduction: a systematic review and meta-analysis. *Minerva Endocrinol (Torino)*, 2021.
495. Swayne, A., et al., Analysing Triggers for Anti-NMDA-Receptor Encephalitis Including Herpes Simplex Virus Encephalitis and Ovarian Teratoma: Results from the Queensland Autoimmune Encephalitis Cohort. *Intern Med J*, 2021.
496. Swift, L., A. Henderson, and C.J. Wu, Self-confidence in clinical skill: A descriptive study of the perspective of first-year nursing students. *Nurse Educ Pract*, 2021. 58: p. 103270.
497. Tanner, H., et al., Consumption of a Low Carbohydrate Diet in Overweight or Obese Pregnant Women Is Associated with Longer Gestation of Pregnancy. *Nutrients*, 2021. 13(10).
498. Tanner, H.L., et al., Ketones in Pregnancy: Why Is It Considered Necessary to Avoid Them and What Is the Evidence Behind Their Perceived Risk? *Diabetes Care*, 2021. 44(1): p. 280-289.

499. Tay, J., et al., Prostacyclin is an endosteal bone marrow niche component and its clinical analog iloprost protects hematopoietic stem cell potential during stress. *Stem Cells*, 2021. 39(11): p. 1532-1545.
500. Taye, B.W., et al., Remoteness of residence predicts tumor stage, receipt of treatment, and mortality in patients with hepatocellular carcinoma. *JGH Open*, 2021. 5(7): p. 754-762.
501. Thang, C., et al., Early Albumin Exposure After Cardiac Surgery. *J Cardiothorac Vasc Anesth*, 2021.
502. Thanigaimani, S., et al., Association of Diagnosis of Depression and Small Abdominal Aortic Aneurysm Growth. *Ann Vasc Surg*, 2021.
503. Thayalan, K., H. Krause, and J. Goh, A retrospective case series on transvaginal repair of rectovaginal fistula performed by a urogynaecology operative team in Australia. *Aust N Z J Obstet Gynaecol*, 2021.
504. Theobald, K.A., et al., Developing a postgraduate professional education framework for emergency nursing: a co-design approach. *BMC Nurs*, 2021. 20(1): p. 43.
505. Thomas, D., et al., Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. *J Allergy Clin Immunol Pract*, 2021.
506. Thomas, J., J. Harraway, and D. Kirchoffer, Non-invasive prenatal testing: clinical utility and ethical concerns about recent advances. *Med J Aust*, 2021.
507. Timmins, H.C., et al., Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. *Oncologist*, 2021.
508. Tobin, J.W.D. and M.K. Gandhi, Discordant solutions to discordant problems. *Blood*, 2021. 137(21): p. 2857-2858.
509. Tobin, J.W.D., et al., A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. *Leuk Lymphoma*, 2021: p. 1-9.
510. Tobin, J.W.D., et al., PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. *Cells*, 2021. 10(5).
511. Tollenaar, L.S.A., et al., Spontaneous twin anemia polycythemia sequence: diagnosis, management, and outcome in an international cohort of 249 cases. *Am J Obstet Gynecol*, 2021. 224(2): p. 213.e1-213.e11.
512. Tong, Z.W.M., et al., The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes. *Febs j*, 2021. 288(17): p. 5042-5054.
513. Trevisanuto, D., et al., Devices for Administering Ventilation at Birth: A Systematic Review. *Pediatrics*, 2021.
514. Tropée, R., et al., The SWI/SNF subunit SMARCD3 regulates cell cycle progression and predicts survival outcome in ER+ breast cancer. *Breast Cancer Res Treat*, 2021. 185(3): p. 601-614.
515. Troskie, R.L., et al., Long-read cDNA sequencing identifies functional pseudogenes in the human transcriptome. *Genome Biol*, 2021. 22(1): p. 146.
516. Troskie, R.L., G.J. Faulkner, and S.W. Cheetham, Processed pseudogenes: A substrate for evolutionary innovation: Retrotransposition contributes to genome evolution by propagating pseudogene sequences with rich regulatory potential throughout the genome. *Bioessays*, 2021. 43(11): p. e2100186.
517. Tseng, H.W., et al., Interleukin-1 Is Overexpressed in Injured Muscles Following Spinal Cord Injury and Promotes Neurogenic Heterotopic Ossification. *J Bone Miner Res*, 2021.
518. Turner, J.M., et al., Evaluation of Pregnancy Outcomes Among Women With Decreased Fetal Movements. *JAMA Netw Open*, 2021. 4(4): p. e215071.
519. Turner, J.M., et al., Phosphodiesterase-5 inhibitors in Pregnancy: Systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes. *Am J Obstet Gynecol*, 2021.
520. Ullah, M.A., et al., DP1 prostanoid receptor activation increases the severity of an acute lower respiratory viral infection in mice via TNF- α -induced immunopathology. *Mucosal Immunol*, 2021. 14(4): p. 963-972.
521. Utter, J. and S. McCray, Supporting Health Care Staff With Family Meals During the COVID-19 Pandemic. *Health Promot Pract*, 2021: p. 15248399211003545.
522. Utter, J. and S. McCray, Vending Machines in Australian Hospitals: Are They Meeting the Needs of the Consumer? *J Nutr Educ Behav*, 2021. 53(2): p. 183-186.

523. Valery, P.C., et al., The Patient's Perspective in Cirrhosis: Unmet Supportive Care Needs Differ by Disease Severity, Etiology, and Age. *Hepatol Commun*, 2021. 5(5): p. 891-905.
524. Van Calster, B., et al., The randomized TOTAL-trials on fetal surgery for congenital diaphragmatic hernia: re-analysis using pooled data. *Am J Obstet Gynecol*, 2021.
525. van der Meij, B.S., et al., Cancer cachexia: an overview of diagnostic criteria and therapeutic approaches for the accredited practicing dietitian. *J Hum Nutr Diet*, 2021. 34(1): p. 243-254.
526. van Driel, M.L., et al., Recognising, supporting and understanding Autistic adults in general practice settings. *Australian journal of general practice*, 2021. 50(3): p. 126-130.
527. van Geest, F.S., et al., Long-term efficacy of T3 analogue Triac in children and adults with MCT8 deficiency: a real-life retrospective cohort study. *J Clin Endocrinol Metab*, 2021.
528. Veenstra, M.M.K., et al., Complications and survival after hybrid and fully minimally invasive oesophagectomy. *BJS open*, 2021. 5(1).
529. Vidyasagar, S., S. Kumar, and A. Morton, Screening for primary aldosteronism in pregnancy. *Pregnancy Hypertens*, 2021. 25: p. 171-174.
530. Wade, R.G., et al., Chlorhexidine versus povidone-iodine skin antiseptics before upper limb surgery (CIPHUR): an international multicentre prospective cohort study. *BJS Open*, 2021. 5(6).
531. Wali, J.A., et al., Impact of dietary carbohydrate type and protein-carbohydrate interaction on metabolic health. *Nature Metabolism*, 2021. 3(6): p. 810-828.
532. Walsh, L.J., et al., Trends in Australian dental prescribing of antibiotics: 2005-2016. *Aust Dent J*, 2021.
533. Walweel, K., et al., Brain stem death induces pro-inflammatory cytokine production and cardiac dysfunction in sheep model. *Biomed J*, 2021.
534. Wang, R. and S.Z. Hasnain, Analyzing the Properties of Murine Intestinal Mucins by Electrophoresis and Histology. *Bio Protoc*, 2017. 7(14): p. e2394.
535. Wang, R., et al., Genetic and pharmacological inhibition of the nuclear receptor ROR α regulates T(H)17 driven inflammatory disorders. *Nat Commun*, 2021. 12(1): p. 76.
536. Wang, R., et al., Gut microbiota shape the inflammatory response in mice with an epithelial defect. *Gut Microbes*, 2021. 13(1): p. 1-18.
537. Wang, Y., et al., ICU Patients' Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data. *Frontiers in Pharmacology*, 2021. 12.
538. Wang, Y., et al., Trends in systemic antifungal use in Australia, 2005-2016: a time-series analysis. *Jpn J Infect Dis*, 2021.
539. Wang, Z., et al., Optimization of liver glycogen extraction when considering the fine molecular structure. *Carbohydr Polym*, 2021. 261: p. 117887.
540. Wang, Z., et al., The effect of high-amylose resistant starch on the glycogen structure of diabetic mice. *Int J Biol Macromol*, 2021. 200: p. 124-131.
541. Warrilow, K.A., et al., Australian women's perceptions and practice of sleep position in late pregnancy: An online survey. *Women Birth*, 2021.
542. Waters, K.A., et al., Sleep and Behavior 24 Months After Early Tonsillectomy for Mild OSA: An RCT. *Pediatrics*, 2021. 148(2).
543. Watts, G.F., et al., Essentials of a new clinical practice guidance on familial hypercholesterolaemia for physicians. *Intern Med J*, 2021. 51(5): p. 769-779.
544. Watts, G.F., et al., Synopsis of an integrated guidance for enhancing the care of familial hypercholesterolaemia: an Australian perspective. *Am J Prev Cardiol*, 2021. 6: p. 100151.
545. Webster, R., et al., Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. *BMC Med*, 2021. 19(1): p. 293.
546. Weerakoon, H., et al., Expression of CD49f defines subsets of human regulatory T cells with divergent transcriptional landscape and function that correlate with ulcerative colitis disease activity. *Clin Transl Immunology*, 2021. 10(9): p. e1334.
547. Werder, R.B., et al., Targeting the P2Y₁₃ Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma. *Am J Respir Crit Care Med*, 2021.

548. Wheelock, M.D., et al., Functional Connectivity Network Disruption Underlies Domain-Specific Impairments in Attention for Children Born Very Preterm. *Cerebral Cortex*, 2021. 31(2): p. 1383-1394.
549. Wiener, P., et al., Whole-genome sequence data suggests environmental adaptation of Ethiopian sheep populations. *Genome Biol Evol*, 2021.
550. Wigg, A.J., et al., Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia. *EClinicalMedicine*, 2021. 36: p. 100919.
551. Wilkes, M.J., et al., The prevalence and burden of recurrent headache in Australian adolescents: findings from the longitudinal study of Australian children. *J Headache Pain*, 2021. 22(1): p. 49.
552. Wilkinson, R., et al., Impact of a Persistent Pelvic Pain Clinic: Emergency attendances following multidisciplinary management of persistent pelvic pain. *Aust N Z J Obstet Gynaecol*, 2021. 61(4): p. 612-615.
553. Wilkinson, S.A., et al., Evaluation of the implementation of a best practice gestational diabetes model of care in two Australian metropolitan services. *JBIM Evid Implement*, 2021.
554. Willis, M., et al., The impact on obstetric and perinatal outcomes in term infants following the introduction of a colour-coded, hierarchical cardiotocography classification system: A retrospective non-inferiority study. *Aust N Z J Obstet Gynaecol*, 2021.
555. Willoughby, M., et al., Circumstances and toxicology of violence-related deaths among young people who have had contact with the youth justice system: a data linkage study. *BMC Public Health*, 2021. 21(1): p. 2207.
556. Willoughby, M., et al., Violence-related deaths among people released from incarceration: systematic review and meta-analysis of cohort studies. *EClinicalMedicine*, 2021. 41: p. 101162.
557. Willoughby, M., et al., Violence-related deaths among people released from incarceration: protocol for a systematic review. *BMJ Open*, 2021. 11(1): p. e045601.
558. Willoughby, M., et al., Violence-related morbidity among people released from prison in Australia: A data linkage study. *Drug Alcohol Rev*, 2021.
559. Wilson, C., J. Lai, and A. Morton, Idiopathic orbital myositis in a pregnant woman. *Obstetric Medicine*, 2021.
560. Wilson, E., et al., Measuring the impact of cardiotocograph decision support software on neonatal outcomes: A propensity score-matched observational study. *Aust N Z J Obstet Gynaecol*, 2021.
561. Wood, A.J., et al., Incorporating Aboriginal women's voices in improving care and reducing risk for women with diabetes in pregnancy - A phenomenological study. *BMC Pregnancy Childbirth*, 2021. 21(1): p. 624.
562. Wood, A.J., et al., Type 2 diabetes after a pregnancy with gestational diabetes among first nations women in Australia: The PANDORA study. *Diabetes Res Clin Pract*, 2021. 181: p. 109092.
563. Woodward, L.J., et al., Visuospatial working memory of children and adults born very preterm and/or very low birth weight. *Pediatr Res*, 2021.
564. Wu, M., et al., Addressing the crisis of congenital syphilis: Key findings from an evaluation of the management of syphilis in pregnancy and the newborn in South-East Queensland. *Aust N Z J Obstet Gynaecol*, 2021.
565. Wu, M.X., et al., Congenital syphilis on the rise: the importance of testing and recognition. *Med J Aust*, 2021. 215(8): p. 345-346.e1.
566. Wu, Z., et al., Development of novel reagents to chicken FLT3, XCR1 and CSF2R for the identification and characterization of avian conventional dendritic cells. *Immunology*, 2022. 165(2): p. 171-194.
567. Wyld, K. and A. Morton, Non-diabetic hypoglycaemia related to opioid toxicity. *Emerg Med Australas*, 2021. 33(5): p. 948-950.
568. Xu, H.G., et al., A mobile mindfulness intervention for emergency department staff to improve stress and wellbeing: A qualitative study. *Int Emerg Nurs*, 2021. 58: p. 101039.
569. Xu, H.G., et al., Effects of mobile mindfulness on emergency department work stress: A randomised controlled trial. *Emerg Med Australas*, 2021.

570. Yamada, M., et al., A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. *Contemp Clin Trials Commun*, 2021. 23: p. 100830.
571. Yang, Y., et al., Investigating the shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. *Nat Commun*, 2021. 12(1): p. 5641.
572. Yap, C.X., et al., Analysis of common genetic variation and rare CNVs in the Australian Autism Biobank. *Mol Autism*, 2021. 12(1): p. 12.
573. Yap, C.X., et al., Autism-related dietary preferences mediate autism-gut microbiome associations. *Cell*, 2021. 184(24): p. 5916-5931.e17.
574. Yeh, J., et al., Impact of establishing a specialized hepatobiliary unit on liver resections in a non-specialized tertiary centre in regional Australia. *ANZ J Surg*, 2021.
575. Yen, H.Y., H.L. Chiu, and H.Y. Huang, Green and blue physical activity for quality of life: A systematic review and meta-analysis of randomized control trials. *Landscape and Urban Planning*, 2021. 212.
576. Yen, H.Y., Y. Liao, and H.Y. Huang, Smart Wearable Device Users' Behavior Is Essential for Physical Activity Improvement. *Int J Behav Med*, 2021.
577. Yeon, J., et al., Vulval lichen sclerosus: An Australasian management consensus. *Australas J Dermatol*, 2021.
578. Young, S.L., et al., Alterations to Placental Glucocorticoid Receptor Expression with Alcohol Consumption. *Reprod Sci*, 2021.
579. Young, S.L., et al., Sotagliflozin, a Dual SGLT1/2 Inhibitor, Improves Cardiac Outcomes in a Normoglycemic Mouse Model of Cardiac Pressure Overload. *Front Physiol*, 2021. 12: p. 738594.
580. Yuan, A., et al., Pneumatosis sinistralis. *ANZ J Surg*, 2021.
581. Zafarmand, M.H., et al., Planned Cesarean or planned vaginal delivery for twins: secondary analysis of randomized controlled trial. *Ultrasound in Obstetrics and Gynecology*, 2021. 57(4): p. 582-591.
582. Zestic, J., H. Liley, and P. Sanderson, Concordance of expert clinicians' interpretations of the newborn's true physiological state. *Pediatr Res*, 2021: p. 1-9.
583. Zhang, H., et al., Mendelian randomization study reveals a population-specific putative causal effect of type 2 diabetes in risk of cataract. *Int J Epidemiol*, 2021.
584. Zhang, J., et al., Comparing the effects of hydrostatic high-pressure processing vs holder pasteurisation on the microbial, biochemical and digestion properties of donor human milk. *Food Chem*, 2022. 373(Pt B): p. 131545.
585. Zhang, Q., et al., Protective Effect of Yi Shen Pai Du Formula against Diabetic Kidney Injury via Inhibition of Oxidative Stress, Inflammation, and Epithelial-to-Mesenchymal Transition in db/db Mice. *Oxid Med Cell Longev*, 2021. 2021: p. 7958021.
586. Zheng, Z., et al., Mechanism of Lentinan Intestinal Absorption: Clathrin-Mediated Endocytosis and Macropinocytosis. *J Agric Food Chem*, 2021. 69(26): p. 7344-7352.
587. Zhuang, A., et al., The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition). *Endocrinology, Diabetes and Metabolism*, 2021. 4(3).
588. Zou, Z., et al., A sensitive and high-throughput fluorescent method for determination of oxidase activities in human, bovine, goat and camel milk. *Food Chemistry*, 2021. 336.
589. Zou, Z., et al., Digestibility of proteins in camel milk in comparison to bovine and human milk using an in vitro infant gastrointestinal digestion system. *Food Chem*, 2022. 374: p. 131704.